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Zebrafish are vertebrate organisms offering many distinct advantages to 
study both genetics and development.  The body of this dissertation describes 
research establishing and using zebrafish to model the p53 pathway.   
The gene p53 is implicated in the vast majority of human tumors.  It is 
known as, “the Guardian of the Genome” because of its functions of monitoring 
and maintaining the fidelity of the genome.  The first resulting manuscript from 
our research centered on developing a zebrafish model for the human syndrome 
Li-Fraumeni.  Dysfunction of the p53 pathway has been shown to be the primary 
cause of their propensity toward tumorigenesis.  We first showed the p53 
pathway is conserved in zebrafish.  An F3 screen was devised and carried out 
using a reproducible apoptotic phenotype seen in p53 deficient fish.  This led to 
the discovery of a viable zebrafish with no functional p53.  These fish develop 
tumors that closely mimic Li-Fraumeni patients providing a zebrafish model to 
study human disease.   
 The next resulting manuscript describes a highly efficient method of 
genotyping zebrafish using high resolution melting analysis (HRMA).  The sheer 
number of zebrafish used in laboratories necessitates a technique that is 
efficient, cost effective and accurate.  HRMA was used to genotype zebrafish 
mutant embryos with 100 percent accuracy, removing the need for restriction 
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enzymes and agarose gel electrophoresis.  This technique worked consistently 
well with three different types of mutations: point mutations, deletions, and 
insertions and is applicable to other model organisms. 
The third manuscript results from a secondary screen of a known 
collection of insertional mutant zebrafish.  A novel gene wdr43 was recovered in 
the screen using a phenotype of p53 pathway activation.  This gene was shown 
to activate downstream targets of p53.  The mutant exhibited specific p53 
dependent phenotypes, including apoptosis. Mutants displayed aberrant mitotic 
spindle formation which appeared to result in chromosomal instability.   
The wdr43 mutant also displayed p53 independent developmental 
phenotypes.  Specifically the gut and eyes appeared to halt differentiation at 
particular stages of development, while other organs of the fish continued to 
develop appropriately.  This ongoing project helps to elucidate the p53 
independent role of wdr43 in development. 
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Zebrafish offer many unique characteristics and distinct advantages which 
make them excellent model organisms for the study of genetics and 
development.  The ability to study genetics in zebrafish stems from the fact that 
zebrafish have many offspring compared to other vertebrate organisms.  In 
mouse, it can be unclear whether genes are functioning as dominant or recessive 
genes based on the small number of pups available from a breeding cross.  
Compared to other model organisms, such as Drosophila or C. elegans, 
zebrafish have the distinct advantage of being vertebrates that live long enough 
to develop diseases similar to humans, such as cancer.  Therefore fish allow the 
opportunity to examine these diseases from a unique genetic standpoint.  The 
large number of offspring from zebrafish also allows the expansion into other 
experimental research approaches such as drug discovery.  Sheer numbers of 
embryos that are attainable from fish allow the possibility of testing many 
thousands of drugs in order to find lead compounds that either activate or inhibit 
specific genetic targets.  Therefore, once genes are identified in fish, the tools 
are in place to take the research to the next level of potential pharmacological 
intervention. 
Zebrafish reach reproductive maturity in approximately two to three 
months.  This length of time allows forward genetics screens to be carried out.  In 
order to carry out a forward genetics screen for recessive genes, it is necessary 





ease of housing large numbers, compared to mice, fish have become an 
important vertebrate model organism for screens.   
Genetics in Cancer 
Cancer is often due to the malfunction of multiple genes.  However, there 
are single gene deficiencies that result in hereditary or familial cancer.  Some of 
the early genes involved in cancer were discovered using linkage analysis in 
human families (e.g., BRCA1 and APC) (King et al., 2003; Spirio et al., 1998).  
The Rb gene provided the basis for proposing the two-hit model in humans 
(Knudson, 1971, 1986).  In this scenario, one copy of the gene is already 
mutated (an inherited mutation) and once the other allele is mutated (a somatic 
mutation, or second hit), there is increased potential for tumor formation.  This is 
in contrast to an individual with two wild type copies of the gene.  Having two de 
novo hits in the same genome would be an extremely rare occurrence.  
Knowledge of genetics and how single gene defects lead to hereditary cancer 
has been extremely important to understanding human disease as well as 
cellular biology.   
P53 was originally discovered due to its increased levels in cells 
transformed with the SV40 virus (Lane and Crawford, 1979; Linzer and Levine, 
1979).  Studies of this protein revealed its role as a tumor suppressor and it was 
coined the “guardian of the genome” (Lane, 1993).  P53 appears to be located at 
the intersection of several important signal transduction pathways, including DNA 





transcription factor explains its importance.  When an upstream signal is 
transduced to activate or stabilize p53, it has the ability to activate a large cohort 
of downstream target genes that drive apoptotic (programmed cell death), growth 
arrest, and autoregulatory pathways (Pietsch et al., 2008). 
The importance of p53 as a tumor suppressor is revealed by evidence of 
p53 mutations in approximately 70% of human tumors (Cadwell and Zambetti, 
2001).  In humans, Li-Fraumeni Syndrome is an autosomal dominant disease 
with affected individuals developing tumors with approximately 85% penetrance, 
and approximately 50-70% percent of these families carry mutations in p53 
(Birch, 1994; Frebourg et al., 1995; Kleihues et al., 1997; Li and Fraumeni, 1969; 
MacGeoch et al., 1995; Varley, 2003). The working model for this syndrome is 
that p53’s normal ability to activate apoptosis ensures that deleterious or 
tumorigenic mutations are not propagated to daughter cells. In the absence of 
functional p53, tumorigenic mutations are allowed to propogate. This syndrome, 
along with mouse models and our recently discovered zebrafish model for the 
disease are discussed in depth in Chapter 2.   
Although mutations in p53 exist in the majority of human cancers, it is 
important to learn what happens in the remaining cancers where p53 is still 
functional.  This is based on the assumption that evading apoptosis is a 
necessity of tumorigenesis.  To propagate mutations, cells must find some 
mechanism to inactivate the pathway that would normally repair mutations or 





genes that potentially function in the same pathway.  It is possible that mutations 
in other genes could allow inactivation of this pathway in cases where p53 is not 
mutated.   
To set up forward genetic screens to find new genes in the p53 pathway, 
we needed to find phenotypes that were indicative of modulation of this pathway 
in zebrafish embryos.  Morpholino technology enables rapid and reproducible 
knock down of specific genes (Nasevicius and Ekker, 2000).  Morpholinos are 
highly stable antisense oligonucleotides that inactivate genes in one of two ways.  
Start site morpholinos are designed to be complementary to the ATG region of a 
gene and prevent translation of the mRNA.  Splice blocking morpholinos bind to 
the splice donor or splice acceptor sites in a gene and either include an intron 
into the spliced product, or delete an exon.  In either case, an optimal morpholino 
will inhibit protein synthesis, effectively abrogating the function of the targeted 
gene.  Although there are distinct benefits of such a rapid method of knocking 
down a gene in vivo, there are also disadvantages.  Morpholinos can have off-
target effects, binding to other genes for which they were not intended.  They can 
bind with weaker efficacy, so the knock down of a gene is incomplete (Robu et 
al., 2007).  In spite of these issues, and with proper controls, multiple 
morpholinos can be used effectively to obtain highly useful information. 
Using a splice blocking morpholino, we were able to identify some p53-
dependent phenotypes that we could use for subsequent genetic screens.  Upon 





reproducible apoptosis in the neural region as well as a tail phenotype.  If we 
inject p53 morpholino into a single cell embryo and irradiate them at the same 
time point, we rescue these phenotypes.  The apoptosis that is visible along the 
CNS, via acridine orange staining, was the basis for the screen described in 
Chapter 2.  The goal of this screen was to find genes that could potentially inhibit 
the irradiation response, or decrease apoptosis in the embryo.  The first gene 
recovered was p53, which served as a proof of principle of our screen, and also 
provided a new animal model of Li-Fraumeni syndrome.  
The screen described above utilized N-ethyl-N-nitrosourea (ENU) treated 
fish.  ENU mutagenesis most often results in single base pair changes and some 
small deletions.  The advantages of ENU mutagenesis is the random, unbiased 
whole genome coverage that results.  In theory, every base pair has the same 
probability of being mutated.  The main disadvantages of ENU mutagenesis are 
the necessity of mapping the causative mutation, and genotyping affected 
animals.  After we discovered the causative mutation in the p53 mutant, I166T, in 
the DNA binding region of the gene, we needed reliable, efficient methods of 
genotyping fish.  With a single base pair change, and no gross embryonic 
phenotype, sequencing these fish was the only reliable genotyping method.  
Other methods to genotype include PCR based Restriction Fragment Length 
Polymorphism (RFLP), derived Cleaved Amplified Polymorphic Sequence 
(dCAPS), and Allele Specific Amplification (ASA) (Botstein et al., 1980; Kwok et 





described in depth in Chapter 3.  In short, RFLP and dCAPS involve a restriction 
enzyme digest of an amplified sequence, where the mutation either creates or 
eliminates the restriction site.  Therefore, different products represent the 
different alleles present in an embryo.  ASA utilizes different PCR primers such 
that the 3’ end binds either mutant or wild type allele.  All of these methods are 
plagued with problems, such as incomplete digestion, or non-specific 
amplification.  Also, DNA gels are necessary in every case. 
We devised a technique for genotyping fish that utilizes a rapid cycle PCR 
(entire reaction in less than 1 hour), followed by a melting curve analysis of the 
products.  Neither agarose gels nor rare restriction enzymes are required.  The 
theory behind this technique is that DNA duplexes will melt at different 
temperatures (Lyon and Wittwer, 2009).  Melting temperature is measured by the 
fluorescence emitted by a stain only when DNA is bound in a duplex.  Upon 
dissociation, fluorescence ceases.  Even a single nucleotide change will result in 
a small difference in Tm.  If the equipment is sensitive enough to detect small 
differences, products could be differentiated, and fish could be genotyped.  
Specific causes of melting temperature elevation and depression are described 
in depth in Chapter 3.  This technique has proven efficacious in multiple types of 
mutations, including SNPs, small deletions, and retroviral insertions. 
Retroviral insertion mutagenesis has become a very useful way of 
disrupting genes in zebrafish.  The next screen described in this thesis takes 





retroviral insertional mutagenesis (Amsterdam et al., 2004; Golling et al., 2002).  
The Hopkins lab devised this technique by injecting single cell embryos with 
retroviruses, to obtain their G0 fish (the original adult fish that will be mated to 
form mutant lines).  They collected and maintained approximately 350 embryonic 
lethal mutant lines.   
Like any other mutagenesis, retroviral insertion has both advantages and 
disadvantages.  The most notable advantage is the ability for rapid mapping of 
the mutation.  Inverse PCR is performed on mutants, with the primers annealing 
to the retrovirus.  A disadvantage of this technique is the biased insertion of 
retroviruses into the genome.  Retroviruses tend to insert into particular regions; 
therefore, whole genome coverage is not possible.   
The next forward genetic screen utilized the Hopkins collection of mutants 
(Amsterdam et al., 2004), and again was focused on finding new genes that 
function in the p53 pathway.  This screen was carried out in multiple steps.  First, 
the mutant collection was examined for fish that exhibited phenotypes indicative 
of the p53 pathway.  As described above, these phenotypes include brain 
necrosis/apoptosis and the curled tail phenotype.  Next, the p53 morpholino was 
injected into mutant lines to see if any of the embryonic phenotypes were rescue 
by the loss of p53.   
It is important to consider the type of genes that would be expected from 
this type of screen.  In essence, we are looking for genes, that when lost, 





apoptosis and growth arrest, resulting in the embryonic phenotype.  The p53 
pathway can be activated in multiple ways, including DNA damage, oncogenic 
activation and chromosomal instability.  Importantly, genes involved in these 
pathways are likely to be recovered in our screen 
DNA Damage 
When DNA damage is sensed by many different genes, the p53 pathway 
is activated.  Double strand breaks in the DNA result from stresses such as 
irradiation, and cause foci of damage where proteins such as ATM and BRCA1 
are localized and involved in repair (Deng and Brodie, 2000; Lavin, 2007).  
CHK2, a kinase, is activated in this case, and in turn activates p53 via 
phosphorylation.  P53 is also activated in single strand breaks in the DNA 
involving a signal transduction with ATR and CHK1 (Chen et al., 2003). 
Oncogenic Activation 
This pathway broadly encompasses genes that are involved in oncogenic 
transformations within cells.  The gene often thought to be immediately upstream 
of p53 is the inhibitor mdm2.  Mdm2 is an E3 ubiquitin ligase that targets p53 to 
be degraded.  It also is target of p53, so it functions in an autoregulatory loop .  
Data suggest the sole function of mdm2 is to regulate p53 (Lozano and Montes 
de Oca Luna, 1998; Reinke and Lozano, 1997).  This has been suggested 
because the early embryonic lethal phenotype of an mdm2 knockout is 
completely rescued in a p53 mutant background (Montes de Oca Luna et al., 





tumor incidence in adulthood.  Genes upstream of mdm2 are p19 ARF as well as 
growth signals, such as Ras (Humbey et al., 2008). 
Chromosomal Instability 
Mutations in genes that cause chromosomal instability also lead to the 
activation of p53.  One of the best described cases is that of Aurora A.  Aurora A 
is a kinase that functions during mitosis and localizes to the centrosome of the 
mitotic spindle.  Mutants in mice deficient in Aurora A have exhibited defects in 
the mitotic spindle, leading to chromosomal abnormalities (Lu et al., 2008).  
Interestingly, an overexpression of Aurora A also leads to chromosomal 
abnormalities.  In both cases, p53 is activated (Cowley et al., 2009). 
Of the 350 mutants, we were able to inject approximately 60 lines that 
displayed either of these embryonic phenotypes.  Of the injected lines, we 
recovered mutants with retroviral insertions disrupting 10 genes.  These mutants 
included known genes in the pathways described above, including 
Topoisomerase II (Topo II) and Replication Protein A1 (RPA1).  Both of these 
genes have been implicated in the DNA damage pathway.  In the absence of 
Topo II, DNA is unable to be unwound appropriately, and double stand breaks 
result (McClendon and Osheroff, 2007).  RPA1 has been noted as having roles in 
DNA replication, DNA repair and homologous recombination (Osman et al., 
2009).  Another gene recovered was Aurora B.  This kinase functions in the 
midzone of the mitotic spindle and phosphorylates several proteins necessary to 





abnormalities exist (Andrews et al., 2003).  This leads to chromosomal instability 
and an activation of p53.  These known genes fall into the categories described 
above, and provide proof of principle that our screen will recover genes of 
interest.  A main component of this thesis is the study of one of the novel genes 
recovered.  The characterization of the p53-dependent roles of this gene, wdr43, 
is described in Chapter 4.  wdr43 appears to play a role in ensuring the normal 
formation of the mitotic spindle in order to correctly segregate the chromosomes.  
Spindle aberrations were apparent in mitotic cells in the mutant. 
Zebrafish mutants have been recovered with documented spindle 
aberrations.  Denticleless, another Hopkins insertional mutant, was identified in a 
screen for mutants that had defective G2/M checkpoints.  Immunohistochemistry 
showed these mutants had aberrant spindle formation due to multiple spindle 
poles (Sansam, GD 2006).  Mechanistically, DTL1 associates with an E3 
ubiquitin ligase, and is responsible for the destruction of CDT1.  Interestingly, 
unpublished data from our lab indicates this mutant is rescued by loss of p53.   
Another mitotic spindle mutant is Casseopia, which possesses in SIL (SCL 
Interrupting Locus).  It was recovered from a screen looking for mutants with cell 
cycle defects.  The fish show spindle abnormalities in a large portion of M-phase 
cells.  Additionally, the mutants display developmental defects (Pfaff, MCB 2007).   
Although we saw a rescue of the wdr43 mutant with the concurrent knock 
down of p53, this did not result in a viable fish.  The wdr43 mutant also had some 





of zebrafish embryos is a distinct advantage when studying development.  In fact, 
many mutants have been described with many different types of developmental 
anomalies.  Examination of APC and Retinoic Acid (RA) deficient fish reveals a 
similar phenotype.  Hallmarks of developmental abnormalities in the APC mutant 
fish are the inability to differentiate gut, retina defect, and the inability to form a 
pectoral fin (Nadauld et al., 2004; Nadauld et al., 2005).  The cellular mechanism 
for why this phenotype occurs is unknown, but is explored in Chapter 5. 
The body of this thesis centers on using zebrafish as a genetic model to 
study the p53 pathway.  Forward genetic screens have helped us to recover a 
p53 mutant that serves as a new model of the genetic syndrome Li-Fraumeni.  
Next, we will describe a novel method of genotyping zebrafish using High 
Resolution Melting Analysis (HRMA).  This method is applicable in a variety of 
mutations and should be applicable to all model organisms.  Also, we recovered 
a mutant line with a retroviral insertion into novel gene wdr43.  Characterization 
of this mutant reveals a role for wdr43 in the mitotic spindle as well as a p53 
independent role in development. 
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Li-Fraumeni syndrome (LFS) is a highly penetrant autosomal dominant 
human familial cancer predisposition. Although a key role for the tumor 
suppressor p53 has been described in LFS, the genetic and cellular mechanisms 
underpinning this disease remain unknown.  Therefore, modeling LFS in a 
vertebrate system accessible to both large-scale genetic screens and in vivo cell 
biological studies will facilitate the in vivo dissection of disease mechanisms, help 
identify candidate genes and spur the discovery of therapeutic compounds. Here, 
we describe a forward genetic screen in zebrafish embryos to identify LFS 
candidate genes, which yielded a p53 mutant that as an adult develops tumors, 
predominantly sarcomas, with 100% penetrance. As in humans with LFS, tumors 
arise in heterozygotes and display loss of heterozygosity (LOH). This first report 
of LOH in a zebrafish cancer model indicates that the Knudson’s two hit 
hypothesis, a hallmark of human autosomal dominant cancer syndromes, can be 
modeled in zebrafish. Further, like some LFS mutations, the zebrafish p53 I166T 
allele is a loss-of-function allele with dominant-negative activity in vivo. 
Additionally, we demonstrate that the p53 regulatory pathway, including mdm2 
regulation, is evolutionarily conserved in zebrafish, providing a bona fide 
biological context in which to systematically uncover novel modifier genes and 
therapeutic agents for human LFS.  
Introduction 
Familial cancers, although rare in the general population, represent 
important starting points to understanding the genetic components and 
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mechanisms of cancer. Much of our knowledge of key cancer-causing genes has 
been gained by studying familial cancers, such as RB in retinoblastoma, APC in 
Familial Adenomous Polyposis (FAP), WT1 in Wilms Tumor, VHL in Von Hippel-
Lindau disease, and others (Field et al., 2007; Ganjavi and Malkin, 2002). These 
familial syndromes often model sporadic cancer in the general population and 
help in devising strategies for cancers treatment. 
Li-Fraumeni syndrome (LFS) is an autosomal dominant, highly penetrant 
cancer predisposition that presents with a wide variety of tumors types at an 
early age (Kleihues et al., 1997; Varley, 2003). Even though a wide variety of 
tumors occur, sarcomas are the hallmarks of the disease. The criteria for 
diagnosis of LFS are the presenting individual has a sarcoma before the age of 
45, and has two 1st degree relatives who develop cancer before age 45 or a 
sarcoma at any age.  Li-Fraumeni–like syndrome (LFL) and incomplete LFS (LFI) 
are similar to LFS, but with slightly different diagnostic criteria. Germ-line 
mutations in p53 have been identified in 50-70% of LFS, 40% of LFL, and 6% of 
LFI families (Birch et al., 1994; Chompret et al., 2000; Frebourg et al., 1995; Li 
and Fraumeni, 1969; MacGeoch et al., 1995).  Chk2 has been suggested to be 
responsible for 5% of LFS families (Bell et al., 1999); however, this has been 
questioned since chk2 -/- mice do not develop tumors (Takai et al., 2002). None 
the less, the genes responsible for the remaining 25-45% of LFS families, 60% of 
LFL families and 94% of LFI are unknown. In four families in which a p53 
mutation was excluded, linkage mapping implicated chromosome 1q23 and at 
least one additional locus (Bachinski et al., 2005), indicating that multiple loci 
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contribute to LFS. However, due to the small size of the families, mapping to a 
single gene on 1q23 and other loci has been difficult. 
Among LFS families there appears to be a genotype-phenotype 
correlation, with a subset of missense p53 alleles conferring more severe cancer 
predisposition (Birch et al., 1998). The idea that specific mutant p53 proteins 
have increased tumorigenic potential not found in null alleles is supported by the 
observation that a disproportionate number of missense, as compared to 
nonsense, mutations are found in Li-Fraumeni families. In vitro studies have 
demonstrated mutant p53 proteins have loss-of-function (LOF) activity (Sigal and 
Rotter, 2000), dominant-negative (DN) activity (Milner and Medcalf, 1991), and/or 
gain-of-function (GOF) activity (Dittmer et al., 1993), perhaps conferring 
advantages for tumor progression (Cadwell and Zambetti, 2001; Varley, 2003).  
In addition to LFS, p53 is mutated in 50-70% of sporadic cancers, making 
it one of the most widely implicated genes in cancer biology (Cadwell and 
Zambetti, 2001). The tumor suppressor p53 is a transcription factor known to 
induce many targets following DNA damage. The outcome of p53 activation is 
predominantly apoptosis (through Puma, Noxa, and Bax) and cell cycle arrest 
(p21 and Cyclin G); both have been shown to be important in cancer prevention.  
While p53 null mice display some of the dominant phenotypes seen in 
LFS, such as autosomal dominance and loss of heterozygosity (LOH) (Clarke et 
al., 1993; Donehower et al., 1992; Jacks et al., 1994), mice with missense 
mutations analogous to those found in LFS (LFS mice) are a better model in that 
they display dominant negative (DN) and gain-of-function (GOF) activity (Lang et 
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al., 2004; Olive et al., 2004). However, the difficulty of forward genetic screens in 
mice and the challenges of mapping in humans, hampered by the small size of 
some LFS families, emphasize the importance of designing genetic approaches 
in other organisms to unravel the p53 pathway and identify new Li-Fraumeni 
cancer genes.  
P53-related genes have been identified in a variety of genetically useful 
invertebrates, including D. melanogaster (Brodsky et al., 2000; Ollmann et al., 
2000), and  C. elegans (Derry et al., 2001; Schumacher et al., 2001). However, 
they lack the p53-like genes p63 and p73, as well as the p53 regulators mdm2 
and mdm4 (Lu and Abrams, 2006). In Drosophila, the p53 pathway appears to be 
simplified; DNA damage activates CHK2, which phosphorylates and activates 
p53 to transcribe apoptotic targets genes such as reaper and hid, thereby 
resulting in cell death. Unlike the mammalian system, Drosophila p53 does not 
induce growth arrest and phosphorylation does not stabilize the p53 protein (Lu 
and Abrams, 2006). This lack of modulated p53 protein stability concurs with 
Drosphila’s lack of the negative regulators mdm2 or mdm4. Therefore, although 
genetically powerful, these invertebrate systems do not recapitulate the 
complexity of the p53 regulatory pathways in mammalian systems.   
Zebrafish are becoming a powerful tool for cancer research (Feitsma and 
Cuppen, 2008; Goessling et al., 2007), in part due to ease of in vivo manipulation 
and the ability to perform both genetic and in vivo drug screens. Zebrafish have 
p53, p63 and p73 genes, as well as the regulatory mdm2 and mdm4 genes (Lu 
and Abrams, 2006). A zebrafish p53M214K mutant was recently identified in a 
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TILLing project (Berghmans et al., 2005). This mutant develops tumors, 
suggesting zebrafish might be a good model for cancer studies. However, these 
tumors were seen with low penetrance and no tumors were found in 
heterozygous fish, indicating this mutant line does not recapitulate LFS. 
Most human familial cancer predispositions are autosomal dominant and 
loss of the functional wildtype allele, referred to as Loss of Heterozygosity (LOH), 
is an important mechanism of the Knudsen two-hit hypothesis for cancer 
progression (Field et al., 2007; Ganjavi and Malkin, 2002). Surprisingly, none of 
the autosomal dominant cancer models in zebrafish undergo LOH, including RP 
mutants (Amsterdam et al., 2004) and an APC mutant (Haramis et al., 2006), 
raising significant concerns that zebrafish does not serve as a genetic model for 
LOH and human tumor formation. 
In this study, we characterized a p53-dependent IR-sensitivity phenotype 
in zebrafish embryos and used this embryonic phenotype to genetically screen 
for novel mutations in LFS genes that give rise to tumors in adults. As proof of 
principle, this screen identified an isoleucine to threonine mutation at codon 166, 
analogous to codon 195 in human, in the highly conserved DNA-binding domain 
of p53.The resulting p53I166T mutant displayed highly penetrant tumorigenesis in 
both the heterozygous and homozygous states, and displayed a high rate of 
LOH, demonstrating for the first time in zebrafish a fundamental mechanism that 
contributes to human cancer. This mutant has the dominant phenotypes of 
human LFS: sarcomas, autosomal dominant tumor formation, and dominant 
negative functional activity. Utilizing the mdm2 knock-down lethal phenotype, we 
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show this p53 mutant is a loss-of-function allele with dominant-negative activities. 
This LFS zebrafish mutant will serve to uncover novel modifier genes and drugs 
capable of modulating the evolutionarily conserved LFS pathway.  
Results 
Genetic Screen for Li-Fraumeni Syndrome in Zebrafish 
Genetic screens in nonvertebrates eukaryotes have been utilized to 
identify components of cancer pathways. However, not all pathway components 
are conserved between simpler eukaryotes and humans. The p53 gene is only 
found in metazoans, and functions as a tumor suppressor only in vertebrates 
(Goessling et al., 2007; Lu and Abrams, 2006). Thus a genetic screen in 
vertebrates would be necessary to identify genes responsible for tumor 
susceptibility in Li-Fraumeni syndrome. 
We designed an F3 recessive genetic screen in zebrafish to identify 
components of the LFS/p53 pathway, using phenotypic response in embryos to 
ionizing (gamma) irradiation (IR) as an assay (Figure 2.1A). Northern blot 
analyses of putative p53 target genes (Supplemental Figure 2.1) and whole 
embryo apoptotic staining at various doses and times were performed to 
determine both the optimal IR conditions (Supplemental Figure 2.2) and p53-
dependence both of target gene induction and apoptotic response (Supplemental 
Figures 2.1 & 2.3). The resulting screen scored for loss of neural tube (NT) 
apoptosis in zebrafish embryos irradiated at 30hpf with 30Gy and assessed 8 
hours postirradiation (hpi). Approximately 1800 F3 clutches from 300 F2 (F1 x 
F1) families, approximately 489 genomic equivalences, were screened, yielding 
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one mutant with IR-resistant phenotype (Figure 2.1A) that segregated with 
Mendelian inheritance. Homozygous mutants were completely viable and fertile.  
 Sequencing of p53 cDNA and genomic DNA from mutant embryos 
revealed a T to C transition at codon 166 (Figure 2.1B), causing an isoleucine to 
threonine change in the DNA binding domain of p53.  This mutation occurs at a 
conserved amino acid position in p53 among vertebrates (Figure 2.1C) and this 
exact mutation, in analogous codon 195 (Figure 2.1C), has been found in many 
human sporadic cancers. We modified a PCR-based mutation detection 
technique (Zhou et al., 2005) to develop a novel differential melting curve assay 
to efficiently genotype embryos and adult p53 mutant fish (Figure 2.1D, further 
details in Supplemental Materials). 
P53I166T Protein Is Stabilized Following DNA Damage but Does Not  
Transactivate p53 Target Genes 
Stabilization of p53 protein is important in the regulation of p53 activity in 
mammals. In wildtype zebrafish, strong induction of p53 protein accumulation 
was observed at 2hpi, which continued through 20hpi (Figure 2.2A). Thus, p53 
protein stabilization in response to irradiation-induced DNA damage is conserved 
in zebrafish. Therefore we tested whether p53I166T mutant protein was stabilized 
with kinetics similar to wildtype p53 protein. Strikingly, mutant p53 protein was 
induced by IR and accumulated with similar kinetics as wildtype p53 protein 




To determine whether the mutant protein can induce p53 target genes, the 
expression of the cell cycle genes p21 and Cyclin G, the p53 regulatory gene 
mdm2, and the apoptotic genes Bax, Puma, and Noxa were assessed in non-
irradiated or irradiated p53+/+, p53I166T/I166T and p53 morpholino (MO)-injected 
embryos (p53 morphants) (Figure 2.2B). The p53 target genes were induced in 
wildtype samples following irradiation, but were not induced in p53 mutant or p53 
morphants. The p53 morphant results indicate that induction of this battery of 
genes is dependent on the presence of functional p53 protein. Although mutant 
p53 protein is stabilized with normal kinetics following IR, it has lost the functional 
ability to induce transcription of p53 target genes in the cell cycle, autoregulatory 
and apoptotic pathways.  
p53I166T/I166T Mutants Have High Rates of Tumorigenesis 
In LFS families, 85% of individuals carrying a p53 mutation will develop 
cancer, and 50% will do so by age 30 yrs (Field et al., 2007). In contrast, 
previously described zebrafish cancer models, p53M214K, ribosomal protein (RP) 
or APC mutations, display only low penetrance tumorigenic phenotypes. To 
determine whether p53I166T mutant fish, like Li-Fraumeni patients, are susceptible 
to increased tumor incidence and penetrance, genotyped cohorts of p53I166T/I166T 
adult fish (n=144) were raised and compared to p53+/+ adult siblings (n=60), 
generated from a heterozygous-heterozygous mutant cross.  The first incidence 
of tumor formation in p53I166T/I166T fish occurred at 269 days (8.8 months), and the 
last 679 days (22.3 months) with a 50% survival at 465 days (15.2 months) 
(Figure 2.3A), indicating that the p53I166T allele results in a fully penetrant tumor 
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phenotype. One advantage of this zebrafish model is that every fish developed a 
tumor that was grossly observable in the tank, in contrast to other zebrafish 
cancer models.  
 Tumors predominantly occurred in three locations: abdomen (64 of 134), 
eye (26 of 134) or flank (22 of 134), with less frequent occurrences in the gills (4 
of 134), rectum (6 of 134) and skin (2 of 134).  There was no difference in the 
onset of abdominal and flank tumors, but significantly later onset of eye tumors 
(Figure 2.3B). Histological analyses of p53I166T/I166T tumors from abdomen (Figure 
2.4A,E,I), eye (Figure 2.4B,F,J), flank (Figure 2.4 C,G,K), or gills (Figure 
2.4D,H,L) indicate they are predominantly soft tissue sarcomas (27/29 were 
STS), like the majority of sarcomas in LFS (Varley, 2003).   
p53I166T/+ Heterozygotes Are Tumor Prone and Exhibit Loss of        
Heterozygosity (LOH) 
LFS and most familial cancer diseases are autosomal dominant diseases. 
In contrast, previously reported zebrafish heterozygous p53M214K mutants do not 
develop tumors (Berghmans et al., 2005). To determine whether the p53I166T 
heterozygous mutants develop tumors, cohorts of heterozygous (n=190) and 
wild-type (n=60) siblings were monitored for tumor burden.  Similar to Li-
Fraumeni patients, heterozygous mutant zebrafish developed tumors at 
significantly increased rates compared to wildtype siblings (Figure 2.5A). As in 
p53I166T/I166T homozygotes, tumors in p53I166T /+ heterozygotes were 
predominantly in the abdomen (15 of 33), eye (2 of 33), flank (4 of 33), gills (3 of 
33), rectum (5 of 33) and skin (1 of 33).  
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A central hallmark of LFS tumorigenesis and Knudson’s two-hit hypothesis 
is Loss of Heterozygosity (LOH), i.e., loss of the wildtype allele in tumorigenic 
tissue. Interestingly, LOH has not been detected in tumors in RP heterozygous 
mutants or APC heterozygous mutant zebrafish (Amsterdam et al., 2004; 
Haramis et al., 2006), raising the significant concern that LOH does not occur in 
zebrafish. To determine whether LOH occurred in tumors in p53I166T/+ fish, pair-
matched tumor and nontumorigenic genomic DNA samples were obtained from 
individual fish and PCR products containing codon 166 were amplified and 
sequenced.  In 87.5% of cases there was clear LOH, with loss of the wildtype 
allele in tumors but not in other tissue from the same individual fish (Figure 2.5B). 
This is the first example of LOH in zebrafish, indicating that the p53I166T 
recapitulates human LFS and opening the possibility of applying genetics to 
elucidate the regulatory mechanisms of LOH.     
p53I166T/I166T Is a Loss of Function Allele that Rescues mdm2                
Knockdown Lethality 
Mdm2 is a transcriptional target of p53 and an E3 ubiquitin ligase that 
binds to p53 and promotes its degradation, thereby providing a negative feed-
back loop in the p53 response pathway. In mouse, mdm2 null is embryonic lethal 
but is viable in the context of p53 null. In contrast to the irradiation response in 
which p53 maintains its feedback regulatory control mechanism, loss of mdm2 
results in unrestrained activation of p53. Thus, loss of mdm2 provides a stringent 
assay for testing whether there are remnants of functionality in mutant p53 
proteins in multiple tissues and many pathways, including apoptosis, cell cycle 
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arrest, and others. For example, mouse p53 loss-of-function (LOF) alleles (p53null 
and p53R172H) are able to completely rescue mdm2 null lethality. In contrast, p53 
hypomorphic alleles (p53pro, p53S389A and p53R172P) do not restore viability to 
mdm2 null mutants (Iwakuma et al., 2004; Jones et al., 1995; Lang et al., 2004; 
Liu et al., 2007; Montes de Oca Luna et al., 1995; Toledo et al., 2006).  
We have shown (Figure 2.2B) that IR induction of mdm2 expression is 
dependent on p53 and is abrogated in p53I166T/I166T embryos. To assess whether 
the other arm of the mdm2-p53 feedback regulatory pathway functions in 
zebrafish, an mdm2 splice-blocking MO that effectively knocks-down mdm2 
mRNA accumulation (data not shown) was used to induce mdm2-dependent 
embryonic lethality. The earliest gross observable mdm2 MO phenotypes occur 
at 14hpf, but are more apparent at 26hpf and 50hpf (Figure 2.6B, H). In mouse, 
loss of mdm2 results in increased apoptosis at the blastocyst stage, but cell cycle 
arrest could not be determined (Chavez-Reyes et al., 2003). Due to accessibility 
of zebrafish embryos, we were able to determine that mdm2 knockdown lethality 
is due to both increased apoptosis (Figure 2.6D) and cell cycle arrest (Figure 
2.6F). Complete rescue by injection of mdm2 mRNA (Figure 2.6J) demonstrates 
this phenotype is not due to MO off-target effects. Rescue of the mdm2 
knockdown lethality by co-injection with p53 MO (Figure 2.6l) indicates that the 
p53-mdm2 regulatory loop described in mammals is conserved in zebrafish.  
Within the context of this epistatic approach, a p53 LOF mutant would be 
predicted to rescue mdm2 knockdown lethality, whereas a p53 hypomorphic 
allele would be predicted to have residual p53 function that would be sufficient to 
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confer lethality in mdm2 deficient embryos. To test whether the p53I166T mutant is 
a LOF or hypomorphic allele, p53I166T/I166T embryos were injected with mdm2 MO, 
and found to be completely viable, providing functional evidence that p53 I166T is a 
LOF mutation (Figure 2.6N). In mammalian tissue culture, loss of mdm2 results 
in stabilization (or lack of degradation) of the p53 protein (Iwakuma and Lozano, 
2003). Western blot analysis revealed that wildtype and mutant p53 protein 
accumulated to comparable levels in wildtype and p53I166T/I166T mutant embryos, 
respectively, following mdm2 MO injection (Figure 2.6O), indicating there is no in 
vivo defect in the mdm2-dependent arm of the regulation of p53I166T mutant 
protein stability. 
The p53I166T Allele Has Dominant Negative (DN) Activity 
Among LFS families there appears to be a genotype-phenotype 
correlation with a subset of missense p53 alleles conferring more severe cancer 
predisposition (Birch et al., 1998). One possibility is that increased tumor 
potential is due to dominant negative (DN) activity, since some, but not all, 
human missense mutations have DN activity when overexpressed in cell culture 
(Milner and Medcalf, 1991), and heterozygous p53R172H murine models respond 
differently to IR compared to heterozygous p53null.  If mutant p53 protein has 
dominant negative activity, it would be capable of reducing the functional activity 
of co-expressed wild-type p53 protein. In order to test this, we designed several 
sensitized assays of p53 function in p53I166T/+ heterozygotes. The prediction is 
that the heterozygotes would have a phenotype similar to the homozygous 
mutants if the p53 mutant protein had strong dominant negative activity, or have 
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an intermediate phenotype if the p53 mutant protein had partial/weak dominant 
negative activity. Conversely, if a p53 mutant protein did not have dominant 
negative activity, the heterozygotes would display a wildtype phenotype.   
Our results from multiple in vivo assays indicate that p53I166T protein has 
DN activity. In the first assay, embryos were treated with low dose (5Gy) IR that 
was sufficient to cause mild apoptosis in wildtype embryos (Figure 2.7B) but no 
apoptosis in p53I166T/I166T homozygotes (Figure 2.7D).  There was also no 
increased apoptosis in p53I166T/+ embryos, indicating the heterozygous phenotype 
(Figure 2.7C) was similar to the homozygous mutant phenotype. In the second 
assay, we observed that p53 mutants were resistant to the curled tail phenotype 
normally induced by 100Gy irradiation (Figure 2.7E,G). Irradiated p53I166T/+ 
heterozygotes (Figure 2.7F) also did not have a curled tail phenotype, again a 
similar phenotypic response in heterozygotes and homogyous mutants indicative 
of a dominant negative activity in the heterozygotes.   In a third assay, to assess 
whether DN activity also occurs in late stage fry, we developed an in vivo 
radiation resistance thymocyte paradigm using transgenic fish that express 
EGFP in mature T cells, under the regulation of the Lck promoter Tg(lck:lck-GFP) 
(Langenau et al., 2004). Eight day old p53+/+; Tg(lck:lck-GFP)/+ and p53I166T/I166T; 
Tg(lck:lck-GFP)/+ fry were irradiated with 0 or 30Gy and imaged the following 
day for EGFP expression. Untreated p53+/+; Tg(lck:lck-gfp)/+ and p53I166T/I166T; 
Tg(lck:lck-gfp)/+ fry were identical in their EGFP expression (data not shown), 
indicating that the p53I166T allele did not alter T cell development or Lck-GFP 
expression. When irradiated, p53+/+; Tg(lck:lck-gfp)/+ fry had severely reduced 
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EGFP expression (Figure 2.7H). In contrast, p53I166T/I166T; Tg(lck:lck-gfp)/+ fry 
retained EGFP expression (Figure 2.7J) similar to nonirradiated controls, 
indicating that the IR induced T-cell apoptosis is p53 dependent. To test 
dominant negative activity the thymocyte assay was repeated with p53I166T/+; 
Tg(lck:lck-gfp)/+ fry. When irradiated, p53I166T/+; Tg(lck:lck-gfp)/+ fry retained 
some EGFP expression (Figure 2.7I), indicating that IR-induced apoptosis in 
thymocytes was at least partially abrogated in p53I166T heterozygotes, suggesting 
the mutant allele has DN activity at older stages as well. Thus, in each of these 
three IR-response assays, the mutant p53I166T protein appeared to have DN 
activity sufficient to block the function of wildtype p53 protein.  
To assess whether p53I166T has dominant negative activity in other cellular 
processes besides the response to irradiation, we used mdm2 knockdown 
lethality as an assay for p53 function. Injection of mdm2 MO into embryos from a 
p53I166T/+ intercross resulted in three phenotypes distributed in a Mendelian ratio 
(Figure 2.7K,L,M), suggesting that the p53 wild-type, heterozygous and 
homozygous mutants each had a distinct phenotype. Embryos were segregated 
into each of these three phenotypic categories, and then individually genotyped. 
Mdm2 morphant embryos with a lethal phenotype were wildtype for p53. 
Morphants with a partially rescued phenotype were heterozygous mutants 
(p53I166T/+). Completely rescued embryos were homozygous mutants  
(p53I166T/ I166T) (Figure 2.7N).  
The intermediate phenotype of the p53I166T/+ heterozygotes injected with 
mdm2 MO is strikingly distinct from the p53 wildtype embryos injected with mdm2 
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MO.  In p53I166T/+ mdm2 morphants, the opaque necrotic head phenotype is 
similar to phenotype in the p53+/+ mdm2 morphants or IR treated embryos, 
suggesting apoptosis contributes to the intermediate phenotype. However the 
phenotype could be due to delay in p53 dependent apoptosis. Alternatively, the 
eye, head, tail and somite appear to develop fairly normal in p53I166T/+ mdm2 
morphants. These tissues also do not appear to undergo apoptosis following 
irradiation, suggesting p53 may have alternative effects, such as cell cycle arrest 
or other outcomes in these tissues and these p53 activities are inhibited by the 
p53 mutant DN activity, thereby making these tissues appear normal in p53I166T/+ 
mdm2 morphants but not p53+/+ mdm2 morphants. Together, this suggests that 
p53I166T has DN activity capable of rescuing some, but not all, aspects of the 
lethal mdm2 knockdown phenotype, In addition, the fact that p53I166T 
heterozygous fish develop tumors, unlike p53M214K heterozygous fish, suggests 
tumor induction might occur in part through DN activity of the p53I166T allele. 
Discussion 
This study provides the first zebrafish mutant that recapitulates the 
dominant phenotype of human Li-Fraumeni Syndrome (LFS), derived from an 
unbiased forward genetic screen. Strikingly, this forward genetics screen utilizes 
a specific irradiation-induced embryonic phenotype to successfully identify 
mutations that give rise to tumors in adults. We show heterozygous p53I166T fish, 
like LFS patients, have a high rate of tumor development and follow Knudson’s 
two-hit hypothesis in which the tumors display LOH at the p53 locus. These 
results demonstrate the evolutionary conservation of the vertebrate LFS pathway 
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and suggest zebrafish genetics will accelerate the discovery of other LFS genes. 
In addition, we have shown at a molecular level that regulation of the p53 
pathway is conserved between zebrafish and mammals. Cell cycle target genes 
(p21, Cyclin G and Gadd45), a regulatory gene (mdm2), and apoptosis genes 
(Bax, Puma, and Noxa) are all induced in a p53-dependent manner in zebrafish. 
Loss of mdm2 in the mouse results in apoptosis (Chavez-Reyes et al., 2003); 
however, cell cycle arrest could not be tested in the blastocyst stage of mdm2 
null embryos. In contrast, the accessibility of zebrafish embryos allowed us to 
demonstrate that the embryonic lethality in mdm2 morphants was due to both 
increased apoptosis and cell cycle arrest. As in mammalian systems, p53 
wildtype and mutant protein are stabilized, and IR-induced apoptosis is p53 
dependent in embryonic neural tube and in thymocytes. 
Among LFS families there appears to be a genotype-phenotype 
correlation with distinct missense p53 alleles conferring a more severe cancer 
predisposition (Birch et al., 1998; Cadwell and Zambetti, 2001). Molecularly, 
some LFS missense mutations in p53 have been shown to be loss-of-function 
alleles, equivalent to truncation or null alleles, whereas other mutations are 
hypomorphic, dominant-negative (DN) and/or gain-of-function (GOF) alleles. In 
addition, LFS models in mouse demonstrated both DN and GOF activity. Here 
we use whole-animal studies to show that the zebrafish p53I166T mutation is a 





Loss of Function 
Within LFS families, 80% of p53 mutations are missense mutations. 
However, not all are complete loss of function (LOF) mutations; some mutations 
have been shown to lose apoptosis but preserve growth arrest function (Aurelio 
et al., 2000). In genetics, the formal definition of a full loss-of-function (LOF) in a 
missense allele is that the missense allele over a deficiency (deletion) mutation 
has the same phenotype as a homozygous deletion mutation. In mouse, p53 null 
and LFS mice were shown to be deficient in p53 dependent neural tube 
apoptosis in vivo and thymocyte apoptosis ex vivo following IR treatment. 
Determining if a p53 missense mutation results in complete loss of function is 
difficult in zebrafish in the absence of a deletion allele. However, we have 
performed multiple assays to assess the function of mutant p53 protein in 
zebrafish, and all results suggest that the p53I166T is a loss-of-function allele. 
First, similar to mutations found in LFS patients, our zebrafish mutant is 
deficient in induction of p53 target genes, including cell cycle, regulatory and 
apoptotic pathway genes (Figure 2.2B). This is in contrast to hypomorphic LFS 
human mutations and some mouse hypomorphic alleles (i.e. p53R172P, p53S389A 
and p53pro). Second, we show that the induction defect is not due to altered 
stabilization of the mutant protein, but instead lies in its inability to transactivate 
target genes. Third, correlating with its failure to induce p53 apoptotic genes, the 
p53I166T zebrafish is deficient in p53-dependent apoptosis in embryonic neural 
tissues and in thymocytes (Figure 2.1A and Figure 2.7J), similar to results from 
p53null and p53R172H mice.  
34 
 
Fourth, in a more global assay, mdm2 knock-down lethality is prevented in 
the p53I166T/I166T background. Following irradiation, p53 continues to maintain its 
feedback regulatory control mechanism. In contrast, loss of mdm2 results in 
unrestrained activation of p53. Thus, loss of mdm2 provides a stringent assay for 
testing whether there are remnants of functionality in mutant p53 protein in 
multiple tissues and many pathways, including apoptosis, cell cycle arrest, and 
others. Mouse LOF mutants, p53Null and p53R172H, both completely rescue mdm2 
loss. However, hypomorphic alleles, p53pro, p53S389A and p53R172P, do not 
rescue the mdm2 null lethality. Fifth, in contrast to the low penetrance of the 
p53M214K allele (Berghmans et al., 2005), the 100% penetrance of tumor 
formation in these mutants suggest p53I166T is a LOF allele. 
Dominant Negative Activity 
Distinct LFS missense mutations in the DNA binding domain have earlier 
cancer onset compared to truncation mutations or LFS mutations lying outside 
the DNA binding domain (Birch et al., 1998). One possibility is that increased 
tumor potential is due to DN activity. Milner and Medcalf (Milner and Medcalf, 
1991) showed that some, but not all, human missense mutations had DN activity 
in cell culture. DN activity was also observed in murine models of LFS, in both 
IR-induced neuronal apoptosis as well as IR-induced thymocyte apoptosis 
studies in heterozygous p53R172H mice, but not in heterozygous p53null mice. To 
assay DN activity in the p53I166T mutant we developed multiple in vivo assays, 
and were able to show DN activity by several criteria. First, p53I166T heterozygous 
fish were partially resistant to both IR-induced embryonic neural apoptosis and 
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thymocyte apoptosis, analogous to the DN activity seen in the p53R172H LFS 
mouse. Second, p53I166T heterozygous fish were able to partially rescue loss of 
mdm2. Third, p53I166T heterozygous fish develop tumors, unlike p53M214K 
heterozygous fish, suggesting this might occur in part through the DN activity of 
the p53I166T allele.  
Protein Stability 
Human tumor and cell culture studies have shown that mutant p53 
proteins are typically very stable. However, we show that in the absence of 
stress, the p53I166T mutant protein is not abundant, and that following IR-induced 
DNA damage or mdm2 loss, the mutant protein becomes stable and more 
abundant, at levels comparable to wildtype p53 protein. This suggests that the 
higher levels of p53 protein in human tumor and cell culture studies may be due 
to constitutively active DNA damage signals in tumors and ongoing cell stress in 
culture, which provide signals that stabilize and activate the p53 protein. This 
difference may confound studies meant to address DN or GOF activities which 
might depend on high protein levels that are increased by DNA damage, lack of 
negative regulation (loss of mdm2), or tumorigenesis. This is consistent with the 
context in which we detect DN activity, and the circumstances in which the LFS 
mice display DN and GOF activities. Further, studies (Terzian et al., 2008) have 
shown that mdm2-/- ; p53R172H/R172H mice develop tumors much faster than 
p53R172H/R172H animals, and that mutant protein is stabilized in non-tumor tissues 
of mdm2-/-; p53R172H/R172H mice. Together, these observations suggest that 
additional activities and phenotypes may manifest when mutant p53 protein is 
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stabilized. The observation of similar p53 mutant protein stability in zebrafish 
implies zebrafish may be a useful model to explore mechanisms of p53 stability, 
either through genetic or pharmacological perturbation in vivo. Furthermore, this 
emphasizes the importance of careful evaluation of p53 mutations in cancer 
patients when considering treatment with p53-activating compounds. For 
example, the use of nutlin and nutlin-like compounds that work by inhibiting 
mdm2 and thereby stabilizing p53, might be therapeutic if wildtype p53 is present 
but could be detrimental if particular mutants in p53 are present. This same 
theme might be applicable to considerations of chemotherapeutics, such as 
doxyrubicin or DNA damaging agents known to stabilize p53. 
A Zebrafish Li-Fraumeni Syndrome Model 
Tumors from LFS families are diverse; however sarcomas are the 
hallmark that defines the syndrome. Correspondingly, the p53I166T fish develop 
primarily sarcomas. Due to the absence of a full set of diagnostic antibodies in 
zebrafish, the exact subtype of these sarcomas has not been determined, but 
they appear histologically to be soft tissue sarcomas (STS), like the majority of 
sarcomas in LFS (Varley, 2003). Do p53I166T fish display the complete spectrum 
of tumors seen in LFS patients? The most prevalent tumor after sarcomas in LFS 
patients is breast carcinoma. Given the absence of mammary glands, it is not 
surprising that breast carcinoma was not observed in p53 mutant fish. However, 
in LFS patients, the 5th and 6th most common cancers are brain tumors or 
hematological tumors, which were not detected in p53 mutant fish. This could be 
due to the time of onset. In LFS patients the mean incidence of soft tissue 
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sarcomas is 15.5 years; however the mean age of brain or hematological tumors 
is 25 years (Kleihues et al., 1997). Therefore, with the high penetrance of STS 
seen in p53I166T fish, it is likely the fish die (or are sacrificed) due to the onset of 
sarcomas before the onset of brain or hematological tumors. Similar observations 
were made for murine knockout of p53. The predominant tumors in these mice 
were lymphomas (not found in LFS patients) and sarcomas, with very few other 
tumors. Another possibility is that genetic background may influence the diversity 
of tumor types, as supported by studies of tumor spectrum changes in p53null 
mice on different genetic backgrounds (Kuperwasser et al., 2000). Both mouse 
and zebrafish have been bred to isogenic or partial isogenic backgrounds, 
whereas human LFS patients are genetically diverse. 
One of the hallmarks of LFS tumorigenesis and Knudson’s two-hit 
hypothesis is loss of the wildtype allele (LOH). In this study we provide the first 
example of LOH in zebrafish, which further demonstrates the similarity of p53I166T 
tumors to human LFS tumors. To date, other zebrafish cancer models have not 
exhibited LOH. The lack of LOH in RP mutants may not be surprising in that 
partial loss of translational efficiencies may be tolerated and tumorigenic, but 
complete loss is likely cell lethal. On the other hand, the fact that APC tumors do 
not exhibit LOH is surprising. Utilizing the p53I166T mutant and the powerful 
genetics of zebrafish provides an opportunity to identify the regulatory 
mechanisms of LOH and their influence on cancer progression.  
One confusing issue in all three LFS models, human, mouse and 
zebrafish, is that tumors from heterozygous individuals often display LOH even 
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though the mutant allele has been shown to have DN activity. There are at least 
three potential explanations for this: 1) DN activity is not against p53 but other 
interacting proteins (potential GOF activity), and in order for a cell to be 
tumorigenic, it still needs to lose the wildtype p53 allele; 2) the DN activity does 
not inhibit all p53 functions, hence the partial rescue of the mdm2 lethality; and 3) 
the DN activity depends on the mutant protein being stabile, as discussed above, 
which does not occur until tumorigenesis has begun. Now that we have identified 
a LFS model in zebrafish, we can begin to address these questions using both 
molecular and genetic techniques. 
Zebrafish: New Directions in Cancer Genetics 
Zebrafish are proving to be a very useful model for studying tumorigenesis 
(Feitsma and Cuppen, 2008; Goessling et al., 2007). With the ability to do 
powerful genetics in zebrafish, future studies can use this mutant p53 allele to 
identify cooperative tumor suppressor genes, p53 modifiers, and modifiers of 
genomic stability. Since most familial tumor suppressors are autosomal 
dominant, and most homozygous mouse tumor suppressor knock-outs are 
embryonic lethal, a dominant/heterozygous screen would be particularly 
rewarding. For example, dominant screens for tumor enhancers in the 
p53I166T/I166T background may identify tumor suppressors as well as regulators of 
p53 protein stability and modulators of mutant p53 DN activity. In addition, since 
tumor onset in p53I166T/+ is largely dependent on LOH, an enhancer screen in the 
p53I166T/+ background could identify modifiers influencing the frequency or timing 
of LOH events. 
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 Zebrafish provide an ideal organism for the discovery of novel cancer 
therapeutics.  Drug screens can be performed on p53I166T/I166T embryos to identify 
compounds that either specifically kill p53 mutant embryos or restore apoptosis 
in these mutant embryos following DNA damage. Identified compounds could 
conceivably be invaluable in fighting cancer since 70% of tumors have p53 
mutations. 
Methods 
Zebrafish Maintenance, Lines and Mutagenesis  
Zebrafish (Danio rerio) were maintained on an Aquatic Habitat system 
(Florida, USA). Embryos were collected from natural matings and raised as 
described (Westerfield, 1995). The Tubingen (TU) wildtype strain was used for 
morpholino oligonucleotides (MO) and mRNA injections. ENU mutagenesis was 
carried out in the AB wildtype background using standard protocols (Mullins et 
al., 1994). Adult male fish were exposed to 4 to 6 weekly treatments of 3.0mm 
ENU (sigma cat# n3385), allowed to recover for 1 month, bred to golden (Mullins 
et al., 1994; Streisinger et al., 1981) to determine mutation frequency and 
subsequently bred to wildtype females to generate F1 fish. F2 families were 
obtained from F1 intercrosses. For p53I166T cancer studies, fry were raised at a 
density of n=30/3L tank until 8 months of age, then maintained at 16 fish/3liter 





Morpholino Knockdown and mRNA Injections 
Morpholino antisense oligonucleotides (Gene Tools, Oregon) and mRNA 
synthesized with a mMessage machine SP6 transcription kit (Ambion) were 
injected into the yolk just under the nuclei of 1- to 2-cell stage embryos in a 
volume of 0.5 or 1.0 nl. p53 splice-blocking morpholino (p53 MO) overlaps to 
splice donor site of exon 2 and intron 2 effectively preventing splicing out of 
intron 2, (5′- cccttgcgaacttacatcaaattct -3′); mdm2 splice-blocking morpholino 
(mdm2 MO) overlaps the splice donor site of exon 4 and intron 4, (5′- 
tgttaagagattcagtacgcaccgc -3′). Working concentrations of p53 MO was 0.35mM 
and mdm2 MO was 0.35mM. The Bcl2 and mdm2 ORFs were cloned by RT-
PCR using primers Bcl2 cDNA f1: accatggctaacgaaatt with Bcl2 cDNA r1: 
cgcagaggctgtcacttc and Mdm2 cDNA f1: ccaaaatggcaacagaga with Mdm2 cDNA 
r1: atttcagtgcctcagctc respectively, and subcloned into the CS2+ expression 
plasmid (Rupp et al., 1994; Turner and Weintraub, 1994). Capped RNAs were 
synthesized from these pCS2+ using the mMessage machine SP6 transcription 
kit (Ambion). The working mRNA concentration for both Bcl2 and mdm2 was 300 
ng/ul. 
Irradiation and Apoptotic Detection 
Apoptosis was assayed following IR treatment (137Cs source) or 
Morpholino injection by soaking embryos in 50 ug/ml Acridine Orange (Sigma) for 
45 min and subsequently destaining for 15 minutes. Photographs were taken 




Genotyping Using Melting Curve Analysis 
Initially the I166T mutation was identified by RT-PCR of total RNA from 
pooled mutant embryos and pooled wildtype embryos using primers p53 cDNA 
f1: atggcgcaaaacgaca with p53 cDNA r1: tagcatcccatcacctta, followed by single 
embryo genomic PCR with the same primers. Genomic DNAs from embryos or 
fin clips were digested in 100ul ELB solution (0.01M TRIS pH 8.3,  0.05M KCl, 
1.5mL  0.3% Tween 20, 0.3% NP40) and 5ul Proteinase K (Roche) at 55oC 
overnight, followed by 10min. at 95oC to inactivate the Proteinase K. Melting 
Curve analysis primers (gcgcctgctggtca  and ctgattgccctccactctt) were designed 
to produce a 40bp PCR product surrounding the point mutation. The PCR 
reactions were performed in 96 well plates (Biorad) with the following PCR 
conditions: 95oC for 10s, 30 cycles of 95oC for 2s, 60oC for 2s, 72oC for 2s, and a 
final cycle of 95oC for 2s, then 45oC for 10s. Each reaction contained 1ul 
genomic DNA, 1x lcgreen+, 1x ExTaq buffer, 1x dNTP, 0.5mm primer1, 0.5mm 
primer2, and 1u ExTAQ. The melting curve analysis is performed on a 
lightscanner (Idaho tech.). 
Protein Analysis and Real-Time PCR 
The quantity of protein loaded on western blots was assessed by 
hybridizing with -tubulin primary antibody (Santa Cruz Biotechnologies) and 
subsequent gels adjusted based on -tubulin results. P53 was detected by 
hybridizing with the ZFp53-9.1 antibody (Lee et al., 2008). For PH3 staining, 
embryos were incubated with rabbit polyclonal anti-phospho-Histone H3 (ser10) 
antibody (1:1,000 dilution) (Santa Cruz Biotechnology). monoclonal p53 specific 
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antibody (ZFp53-9.1) Real time RT-PCR was performed on a light cycler PCR 
machine (Roche).The following primer sets were used: for p21 
(SG1:tgacatcagcgggtttacag and i102:ttctgctgcttttcctgaca), for Cyclin G 
(C11:ccaccatgattgaccaggtgacc and C15:agcagcacagacccacac), for mdm2 
(SG76:ctcggtgctgttcttggagt and SG77:cactgcttctcctcctcctg), for Bax 
(SG66:acagggatgctgaagtgacc and SG67:gaaaagcgccacaactcttc), for Puma 
(i97:acgctgtcttccttcagagg and i98:cctgcagaaaattcccagag), for Noxa 
(i91:atggcgaagaaagagcaaac and i92:cgcttcccctccatttgtat), for p53 
(SG72:accccggatggagataactt and SG73:cccagcaactgaccttcctgag), and for -actin 
(SG86:ggtatgggacagaaagacag and SG87:agagtccatcacgataccag). Experiments 
were done in triplicate and normalized to -actin. 
Tumor Analysis 
Adult fish were screened weekly for tumors and/or missing/dead fish. Fish 
identified with tumor burden were fixed in 10% neutral buffer formalin (VWR).  A 
portion of each tumor from abdomen burdened fish was flash frozen along with a 
fin clip for future DNA-RNA analysis. Kaplan Meijer analysis was performed using 
Graphpad Prism 5 analysis. Tumor burdened fish were sectioned and H&E 
stained for histological analysis. LOH analysis was performed by sequencing of 
PCR products (primers: gtgctgttaaagccaccaca and ggtcctacaaaaaggctgtga) from 






Light and fluorescent dissection images were taken on an Olympus 
SZX12 with an Olympus S97809 color CCD camera. LCK-EGFP images were 
taken using an Olympus Fluoview FV300 laser-scanning confocal microscope. 
The fluorescent images presented represent the sum of multiple focal planes 
through the embryo (z-series) assembled using ImageJ (NIH) and Photoshop 
(Adobe) software. 
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Figure 2.1:  Identification of the p53 I166T mutation. (A) F3 screen for LFS 
mutants. Males were treated with ENU mutagen (G0) and bred to generate F1 
fish, each of which is genetically unique and heterozygous for many mutations. 
To propagate heterozygotes, F1’s were intercrossed to generate F2 fish which 
are also heterozygous for a particular mutation. F2’s were intercrossed to 
generate F3 offspring, one-quarter of which are homozygous for a particular 
mutation. These F3 clutches were irradiated at 30hpf and scored for Acridine 
orange (AO) staining (50ug/ml) 8hpi. Approximately 1800 F3 clutches from 300 
F2 (F1 x F1) families were screened, yielding a family in which one quarter of the 
embryos (33 of 130) embryos displayed resistance to IR-induced apoptosis. (B) 
Sequence analyses of genomic PCR products of two WT and one mutant 
embryo from F2 heterozygous crosses. Mutants were homozygous for a thymine 
to cytosine transition in codon 166. (C) Amino acid sequence comparison of the 
human, mouse, chicken, and zebrafish around codon 166 in zebrafish (codon 
195 in human; * marks the mutated Ile codon). (D) Melting curve analysis of PCR 
















































































Figure 2.6:  mdm2 knockdown embryonic lethality is rescued in p53 morphants 
and p53I166T/ I166T mutants. (A, C, E) Embryos injected with water or (B, D, F) with 
mdm2 MO were assessed at 26hpf by (A, B) Transmitted-light microscopy, (C, D) 
acridine orange staining for apoptotic cells and (E, F) phospho-Histone H3 (PH3) 
specific antibody staining (C, D). Mdm2 morphants displayed (B) embryonic 
lethality, likely due to both (D) increased apoptosis and (F) decreased cell 
cycling. With mock (water) injections as controls (G, I, K, M), mdm2 morpholino 
injections (H) yield a readily discernable lethal phenotype at 50hpf. (J) As a 
control for non-specific morpholino effects, co-injection of 150 pg mdm2 mRNA 
rescues the mdm2 MO phenotype. (L) Co-injection of p53 MO rescues mdm2 
MO lethality, indicating that loss of p53 function abrogates loss of mdm2 
phenotype. (N) Injection of mdm2 MO into p53I166T/I166T embryos did not yield the 
mdm2 lethal phenotype, indicating that the p53 mutant has loss-of-function 
similar to p53 MO. (O) p53 protein levels were assessed using anti-p53 antibody 
(ZFp53-9.1) on western blots of extracts from p53+/+ and p53 I166T/I166T embryos 
that were un-irradiated (no IR), irradiated with 30Gy (IR), or injected with mdm2 
MO (M2 MO). Extracts of wild-type embryos injected with p53 MO injected 







































































Figure 2.7:  p53I166T/+ dominant negative phenotypes. (A) Neural tube in the trunk 
and tail of non-irradiated p53+/+ embryos have a low level of apoptosis, detected 
with acridine orange. (B) Apoptosis is increased in embryos 8 hours post 5Gy IR. 
In contrast, (C) p53I166T/+ and (D) p53I166T/I166T did not display increased apoptosis 
at 8 hours post 5Gy IR. (E) Wildtype embryos have a curled tail phenotype at at 
20 hours post 100Gy IR, whereas both (F) p53I166T/+ and (G) p53I166T/I166T did not 
display a curled tail phenotype. (H-J) Confocal analysis of EGFP expression at 
9dpf in p53+/+; Lck-EGFP/+ (l), p53I166T/+; Lck-EGFP/+ (m), and p53I166T/I166T; Lck-
EGFP/+ (n) fish at 1 day post 30Gy IR. Insets are higher magnification of EGFP 
expression.  As another test for DN phenotypes, embryos from a p53I166T/+ 
intercross were injected with mdm2 MO, and sorted by phenotype at 24 hpf: (K) 
25.4% had a severe lethal phenotype, (L) 52.7% had a partially rescued 
phenotype, and (M) 21.9% had a rescued phenotype. (N) Melting curve analysis 
of PCR products from individual genomic DNA samples from embryos with 
severe (black), partial (red) and rescued (blue) phenotypes, which corresponded 





















































Supplemental Experimental Procedures 
Northern Blot Analysis of p53 Target Genes 
Total RNA was obtained from pools of approximately 30 zebrafish 
embryos using Trizol reagent (Invitrogen). Zebrafish p21 and Cyclin G were 
cloned by RT-PCR (Ambion) of irradiated embryos (30gy 6hpi), using primers 
p21 cDNA f1:atggcggcgcacaagc with p21 cDNA r1: cactagacgcttcttggc, and 
cyclin G cDNA f1:ccaccatgattgaccaggtgacc with Cyclin G cdna 
r1:tcttaacaagcatattcagg. Gadd45 was a gift from Dr. Majors. Probes were 
random labeled with -p32-dCTP using primer-it II random primer kit (Stratagene). 
Northern blots and hybridization were performed as per instruction of 
NorthernMax®-Gly Kit (Ambion).  Fifteen ug of total RNA were loaded per lane.  
Supplemental Results 
Conservation of the p53 Transcriptional Targets 
We asked whether components of the p53-response pathway, including 
p21, Cyclin G, Gadd45, and Mdm2 are induced by irradiation. Northern blot 
analysis of total RNA collected 6hpi from 36hpf embryos treated with 100Gy 
indicated that all of these target genes were indeed induced (Supplemental 
Figure 2.1A). Embryos injected with the p53 MO were refractory to this induction, 
indicating these target genes are bona fide targets of the p53 pathway in 
zebrafish (Supplemental Figure 2.1A). The induction kinetics of p53 target genes 
with a low dose of 10Gy (Supplemental Figure 2.1B) or a high dose of 100Gy 
(Supplemental Figure 2.1C) were assayed.  At either dose, p53 target genes 
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were induced within 2 hours, with higher induction levels in the 100Gy samples, 
and maintained through 24hpi. To determine the optimal dose for transcriptional 
induction, analysis was performed on embryos 36hpf and 6hpi at different doses 
(Supplemental Figure 2.1D). For p21 and mdm2, significant induction was 
detected at 20Gy, however maximal induction was at 60Gy. 
p53-dependent Apoptosis in Zebrafish Embryos 
Apoptosis is one of the key mechanisms by which p53 prevents cancer. 
In-vivo studies in the mouse have shown that p53 null embryos are deficient in 
irradiation-induced apoptosis in neural tissues (Lee et al., 2001). To determine 
whether similar apoptosis occurs in zebrafish, we irradiated embryos and then 
used Acridine Orange (AO) to stain apoptotic cells. Initially embryos were treated 
with 100 gray (Gy) of IR at 30 hours postfertilization (hpf), and strong apoptotic 
staining was found in the neural tube (NT) 6 hours postirradiation (hpi). Doses of 
irradiation and time post-IR were optimized for apoptosis detection.  Very little 
apoptosis was seen in untreated embryos at 32, 36 and 50hpf (analogous to 
2hpi, 6hpi and 20hpi; Supplemental Figure 2.2A-C) and at 2hpi in embryos 
treated with 5, 30 or 100Gy irradiation (Supplemental Figure 2.2 A,D,G, or J). 
5Gy produced low levels of apoptosis at 6 and 20hpi (Supplemental Figure 2.2E, 
F). In contrast, 30 and 100Gy produced very strong AO staining at 6hpi that 
persists through 20hpi (Supplemental Figure 2.2H,I,K,L).  Interestingly, a curled 
up tail phenotype was observed in 100% (n=50) of embryos treated with 100Gy 
(Supplemental Figure 2.2L inset) and 32% (n=50) of embryos treated with 30Gy 
(Supplemental Figure 2.2I inset).  
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 To determine whether apoptosis in the NT and the curled tail phenotype 
are p53-dependent, a p53 splice-blocking morpholino oligonucleotide (MO) was 
utilized. RT-PCR and western blot analyses revealed the p53 MO effectively 
knocked down wildtype (WT) p53 mRNA (data not shown) and protein levels 
(Figure 2.2O). p53 MO-injected embryos irradiated at 30hpf with 30Gy or 100Gy 
were stained with AO at 6hpi, or scored for curly tail phenotype at 20hpi. Both 
phenotypes were rescued in p53 MO-injected embryos (Supplemental Figure 
2.3E, H). In mammalian tissue culture, p53-dependent apoptosis can be inhibited 
by overexpression of Bcl2 (Cadwell and Zambetti, 2001). To test whether p53-
dependent apoptosis can be inhibited by Bcl2 overexpression in zebrafish, 
embryos were injected with Bcl2 mRNA at 1-2 cell stage, and then treated with 
30Gy or 100Gy IR at 30hpf. Unirradiated injected embryos had no gross 
morphological phenotypes (Supplemental Figure 2.3C), indicating that Bcl2 
overexpression does not cause development defects. Embryos injected with Bcl2 
mRNA were resistant to apoptosis normally induced by 30Gy (Supplemental 
Figure 2.3F), and the curly tail phenotype invariably induced by 100Gy 
(Supplemental Figure 2.3I). This demonstrates that the curly tail phenotype is a 
useful indicator of IR-induced p53-dependent apoptosis. 
Differential Melting Curve Analysis to Genotype Zebrafish Mutants  
Genotyping missense mutations are often difficult to do in a fast, efficient 
and inexpensive manner.  Using a novel PCR-based genotyping technique of 
differential melting curve analysis, previously used to scan human samples for 
mutations in specific disease genes (Zhou et al., 2005), we have been able to 
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efficiently genotype embryos and adult mutant fish. The PCR is designed to 
generate a small amplicon (~40bp) surrounding the point mutation. The T to C 
transition mutation in p53I166T results in a 1-2oC difference in the melting 
temperature (Tm) of the mutant and WT PCR products that can be resolved by 
fluorescent melting curve analysis (Figure 2.1D). Importantly, heterozygous fish 
can also be identified because the products from the two alleles resolve at two 
peaks (Figure 2.1D). Sequencing confirmed the predicted genotyping in 24 of 24 
samples.  
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In order to facilitate high throughput genotyping of zebrafish, we have 
developed a novel technique that uses High Resolution Melting Analysis (HRMA) 
to genotype heterozygous and homogyzous mutants.  This one hour technique 
removes the need for restriction enzymes and agarose gels, while maintaining 
the ability to ensure the PCR reactions amplify the desired products through 
melting curve profiles.  We have been able to reliably genotype a wide variety of 
mutations including two zebrafish point mutants (APCmcr and P53I166T), as well as 
a small deletion mutant (BAP28y75) and a retroviral insertion mutant 
(WDR43hi821).  Although we apply this technique to zebrafish mutants, the same 
technique can be applied other model organisms. 
Introduction 
Zebrafish as a genetic model organism is coming of age. Considering the 
relative ease of maintaining large numbers of mutant lines, and large numbers of 
fish within each mutant line, genotyping on a large scale necessitates the need 
for efficient and high throughput genotyping techniques. Mutant lines of zebrafish 
result from multiple types of mutations, increasing the complexity of genotyping.  
ENU mutagenesis, the predominate mutagen used in zebrafish, most often 
results in a single base changes, although small deletions and insertions do 
occur (Noveroske et al., 2000).  The second most common approach is 
insertional mutagenesis, using either retroviral insertions (Golling et al., 2002) or 
transposable element insertions to disrupt genes (Balciunas and Ekker, 2005). 
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Therefore development of effective ways of genotyping these mutations is 
necessary. 
Faster, more efficient methods of genotyping are always desirable 
provided they can maintain 100% accuracy.  Therefore techniques/protocols 
designed in a high-throughput manner where time consuming steps are 
eliminated, are sought after.  With the advent of PCR to amplify genomic DNA, 
classical genotyping techniques involving Southern blots and radioactivity (RFLP 
and SSCP) have been phased out. Some PCR-based approaches use the 
fortuitous creation or elimination of a restriction site by the mutation.  Most 
methods, with the exception of outright sequencing, require PCR products to be 
run an agarose gel.  When hundreds or thousands of individual genotypes are 
necessary, this task is time consuming and expensive. 
PCR-based RFLP (Restriction Fragment Length Polymorphism) is a useful 
technique only if a mutation either creates or eliminates a specific restriction site.  
In this assay, PCR primers are designed so the region of interest in amplified.  
This product is digested with the appropriate restriction enzyme and the 
digestions are run on an agarose gel. The genotype is determined to be 
homozygous mutant, heterozygous, and homozygous wildtype depending on the 
restriction pattern (Botstein et al., 1980). 
dCAPS (derived Cleaved Amplified Polymorphic Sequence) is similar to 
PCR-based RFLP in that restriction digest patterns are used to determine 
genotype.  The difference is one or more mismatches are also introduced into the 
PCR primer, so that the additional mismatches, together with the mutation, 
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creates a specific restriction site in the amplified product.  Again, the digested 
PCR reaction is run on an agarose gel and the genotype is determined based on 
the corresponding restriction digest patterns (Neff et al., 1998). Unfortunately, 
these techniques are plagued by incomplete digestion that can result in 
genotyping errors (i.e., homozygous mutants mislabeled as heterozygous). In 
addition, the restriction enzymes required are often rare and expensive. 
ASA (Allele-Specific Amplification) is another PCR-based method.  Two 
different PCR reactions are performed with two different forward primers, one 
specific to the wild type allele and the other to the mutant. In this case, the 3’ 
terminal nucleotide of one primer corresponds to the point mutation in the wild 
type, and in the other the 3’ position corresponds to the mutant sequence.  
Technical details of annealing and amplification of such mismatched sequence 
determine the specificity of this method (Kwok et al., 1990; Newton et al., 1989).  
Unfortunately this technique is riddled with false positives due to mispriming 
during PCR. 
Retroviral insertion mutations (or insertions of other exogenous DNA 
sequences such as transposable elements) are typically genotyped with PCR 
amplification specific to either the retrovirus insertion site or wild type DNA.  
These reactions can be performed separately, one for the wild type allele and 
one for the mutant, or they can be multiplexed. However, multiplexing can be 
difficult due to allele specific differences in amplification kinetics. In this case, a 
single forward primer is used.  Reverse primers are designed such that one will 
anneal to the DNA specific to the retrovirus, and another will anneal specifically 
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to wild type DNA.  In the multiplex reaction, primers are designed such that the 
PCR products of the mutant and wild type allele are distinguishable by size on 
agarose gels.  If the reaction works appropriately, homozygous mutants will have 
only the mutant product visible on a gel, heterozygous animals will have both 
products, and homozygous wild type animals will have only the wild type product 
visible.  This technique is very accurate, although time-consuming due to long 
PCR reactions and the need for agarose or other high resolution gels. 
If none of the above techniques apply, sequencing of DNA is always an 
option to genotype animals.  In this case, PCR primers are designed to flank the 
region of interest, and DNA is amplified.  These products can be sequenced to 
reveal genotypes of individual animals.  This genotyping method avoids manual 
agarose gels.  Nevertheless, the time and expense of sequencing is a distinct 
disadvantage. 
High resolution melting analysis (HRMA) is a homogeneous method of 
PCR product analysis that does not require any processing after PCR.  
Applications include mutation scanning (Reed and Wittwer, 2004), genotyping 
(Liew et al., 2004), and sequence matching (Zhou et al., 2004). Primarily applied 
to humans, these techniques have been recently reviewed (Erali et al., 2008; 
Farrar JS, 2009; Reed et al., 2007; Wittwer, 2009). 
We have developed an efficient and accurate method of genotyping 
zebrafish that detects multiple types of mutations.  We demonstrate genotyping 
for single base pair substitutions, a deletion, and a retroviral insertion in a fast 
and efficient manner without the need for agarose DNA gels.  This method uses 
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high resolution melting analysis to determine homozygous mutants, 
heterozygotes, and homozygous wild type fish.   
Results  
To overcome the drawbacks of present genotyping techniques three main 
improvements need to occur:  1) remove the need for inefficient and expensive 
restriction enzymes; 2) remove the need for agarose gels or other post-PCR 
steps, while maintaining discrimination of nonspecific products; 3) increase the 
speed at which genotyping is achieved. The use of High Resolution Melting 
Analysis (HRMA) achieves these three goals. 
 The theory behind HRMA is the use of a highly sensitive imaging machine 
(for our experiments we use the LightScanner®) that quantifies double stranded 
DNA over a range of temperatures. Double stranded DNA quantification is 
achieved through the use of a DNA dependent fluorescent chemical LCGreen® 
Plus. When bound to double stranded DNA light is emitted.  As the samples are 
heated, fluorescence emission is constantly monitored.  Once the melting 
temperature of a specific duplex is reached, a dramatic decrease in fluorescence 
is detected.  Derivative melting curves are obtained and plotted as the negative 
change of fluorescence per unit time (-dF/dT) on the ordinate (y-axis) for each 
temperature increment on the abscissa (x-axis).  Small changes, even single 
nucleotide polymorphisms, create changes in the melting temperature of a DNA 
duplex.  Here we apply HRMA to genotype two missense mutations, a small 
deletion and a viral insertional mutant. 
76 
 
This technique requires no restriction enzymes, no agarose gels, and 
since the PCR products are less than 60 bp, the entire PCR reaction and melting 
analysis can be done in less than 1 hour. In addition, the specificity of the PCR 
product can be determined by the conformity of the melting curves, i.e. if there is 
a contaminant in the PCR reaction, additional peaks will be identified. 
Single Nucleotide Polymorphism (SNP) Detection  
ENU is commonly used as a mutagen in forward genetics.  The most 
common mutation caused by ENU is a single base pair change (Noveroske et al., 
2000), resulting in a single nucleotide polymorphism (SNP) that distinguishes 
wildtype and mutant alleles.  We have identified a p53 mutant zebrafish line via 
an ENU induced F3 forward genetics screen (Parant et al., 2009).  The mutation 
is a TC transition that creates I166T in the DNA binding region of the gene.  
Because the p53 homozygous mutant line is completely viable and has no 
morphological differences, molecular genotyping of individual zebrafish is 
necessary.  Initially, direct sequencing of the region including the mutation was 
the only reliable method to identify genotypes.  Therefore, we designed primers 
flanking the mutation site (Figure 3.1A).  The entire PCR product is 39 base 
pairs.  In general, the smaller the PCR products are, the larger the Tm difference 
will be. The single base difference between wild type and mutant DNA duplexes 
creates approximately a 1.5oC Tm difference between wild type and mutant 
alleles. To test this, we acquired 48 DNA samples, each representing one 
embryo from a heterozygous-heterozygous cross. Upon melting the PCR 
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products, we observe a difference in the melting curve pattern between 
homozygous wild type and homozygous mutant embryos (Figure 3.1B). 
Significantly, the parameters of our protocol also allow us to assess 
heterozygosity.  At the end of the PCR program the samples are heated to 95oC 
and quickly cooled resulting in heteroduplex formation. Therefore, in addition to 
having an intermediate Tm (~80oC from the wildtype and mutant homoduplexes), 
heterozygotes have lower Tm products due to the instability of heteroduplexes.  
To test this on another missense allele, we designed primers to flank a 
TC missense mutation in APC (Hurlstone et al., 2003).  The PCR product 
produces a 53 base pair product that is predicted to have a 1.5oC Tm difference 
(Figure 3.1C). Forty-eight DNA samples were analyzed, each from one embryo 
of a heterozygous-heterozygous cross. Again melting curve analysis produced 
three distinct melting curves (Figure 3.1D). In this case the mutant allele has the 
cytosine nucleotide and therefore has the higher Tm while the heterozygous 
sample produces an intermediate homoduplex peak and a separate heteroduplex 
peak.  
The p53 genotypes (12 wildtype: 24 heterozygous: 12 mutant) and APC 
genotypes (11 wildtype: 25 heterozygotes: 12 mutants) follow the expected 
Mendelian ratio of 1:2:1. In addition, sequencing of 24 individual samples from 
p53 crosses and 24 individual samples from APC crosses indicated that the 




Deletion Detection   
In addition to SNP detection we wanted to assess whether HRMA would 
provide genotyping of small deletions in zebrafish. The BAP28 mutant zebrafish 
line has a five base pair deletion in exon 2 (Azuma et al., 2006).  Primers were 
designed to immediately flank the deletion, resulting in a 46 bp wild type product 
and a 41 bp mutant product with a 1.6oC Tm difference (Figure 3.2A).  Analysis 
of 48 DNA samples, each representing one embryo from a heterozygous-
heterozygous cross produced three distinct melting curves (Figure 3.2B). In this 
case the smaller mutant homozygote has the lower Tm and the heterozygote 
appears as an intermediate Tm product and a heteroduplex product. Like the p53 
and APC genotyping, the BAP28 genotypes (12 wildtype: 25 heterozygotes: 11 
homozygous mutants) follow a Mendelian ratio of 1:2:1, and all 24 individual 
genotypes were verified by sequencing.  
Retroviral Insertion Detection 
Insertional mutagenesis in zebrafish has become a common and efficient 
method of gene disruption (Balciunas and Ekker, 2005; Golling et al., 2002).  We 
wanted to design a method by which HRMA could be used to genotype specific 
retroviral insertions in zebrafish. The mutant line hi821 (Amsterdam et al., 2004) 
has a retroviral insertion within the second intron of the gene wdr43 (Figure 
3.3A).  Primers were designed to produce a small product with Tms that 
distinquished between wildtype and mutant alleles (Figure 3. 3B).  The forward 
primer (in intron 2, 5’of insertion site) binds both mutant and wild type alleles.  
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The reverse primers are specific to the allele they are amplifying (i.e one in intron 
2, 3’ of insertion site, and the other near the 5’ end of the LTR of the retrovirus) 
(Figure 3.3A).  Therefore, in the homozygous wild type or mutant fish, only one 
product was amplified with a unique Tm (Figure 3.3C).  Although Primers A and 
B, or A and C2 could theoretically amplify a product from the mutant allele, the 
large size of the product (7+ KB), along with the short elongation time (4 
seconds) selected against amplification of such products. In addition, in cases 
where larger products might be amplified, the Tm of these products would be 
high and easy to exclude from analysis.  In heterozygotes, both products were 
amplified.  These products had vastly different melting temperatures and the 
three different genotypes were readily detected (Figure 3.3C). Note that an 
important step in the analysis of insertional mutants is that the PCR reaction is 
not heated to 95oC at the end of the PCR program, and an additional 
72oCelongation step is added to ensure that only homoduplexes are formed. 
Genotyping of wdr43 (12 wildtype: 24 heterozygotes : 12 mutants) followed 
Mendelian inheritance. All 24 genotypes were individually confirmed using PCR 
primers that amplify the wild type allele (583 bp) and mutant allele (230 bp), 
followed by agarose gel separation.  
Discussion 
Three different types of mutations in zebrafish were easily genotyped by 
high resolution melting analysis (HRMA).  The advantages of this method over 
other techniques are numerous.  The time and processing necessary for PCR 
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and melting is much less than that of other methods.  PCR can be performed 
rapidly and the melting curve analysis is much quicker than running agarose 
gels.  There is no need to utilize rare and expensive restriction enzymes.  The 
efficacy and specificity of PCR with high resolution melting removes the 
uncertainties of downstream analysis, such as restriction digestion that is prone 
to error. 
HRMA technology could be easily applied to other genomic samples from 
zebrafish (such as adult tail-clip DNA), and to genomes of other model 
organisms. Because the sensitivity of melting curve analysis allows detection of 
single nucleotide differences, whole genes can be scanned to find where 
mutations reside. Large human genes such as BRCA1 (van der Stoep et al., 
2009) and CFTR (Montgomery et al., 2007) are more efficiently analyzed by 
scanning rather than sequencing.  Human (Liew et al., 2004) and plant (McKinney 
JT, 2009) genotyping and speciation of microorganisms (Cheng et al., 2006) are 
common applications. 
TILLING is a technique used in zebrafish to identify mutations in a specific 
gene following ENU mutagenesis (Till et al., 2003).  This cumbersome technique 
involves digestion with a rare, heteroduplex specific enzyme, Cel1, to detect 
mismatched DNA, followed by gel separation and imaging.  The protocols are 
tedious and required equipment prohibitively expensive.  Similar to mutation 
scanning in humans, genes could be scanned using HRMA to achieve a similar 
outcome with less expense and time than TILLING.   
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It is also possible to conduct HRMA on different machines, such as the 
Roche Lightcycler® 480 or the Qiagen Rotor-Gene Q.  The sensitivity of these 
machines may not be as high as the Lightscanner, but if the products have 
sufficiently large Tm differences, they may be viable options.  The range of 
possibilities for which HRMA can be used continues to increase (Vossen et al., 
2009).  It has become the most efficient method of genotyping animal models in 




Embryos were placed in 96 well plates, embryo water was removed, and 
100 uL of ELB (10 mM TRIS pH 8.3, 50 mM  KCl, 0.3%  Tween 20, 0.3% NP40, 
1 mg/ml Prot K) was added to each well and then incubated at 55oC for 4 hours.  
The plates were then heated to 95oC for 15 minutes to inactivate the Proteinase 
K. 
PCR and Melting Curve Analysis 
PCR was performed in an MJ Research 96 well PCR machine. All 
reactions were done in black/white 96 well plates (BioRad cat #HSP9665).  PCR 
reaction protocols for SNP detection and small deletion detection were 95oC for 
15 seconds, then 40 cycles of 95oC for 2 seconds, 60oC for 2 seconds, and 72oC 
for 2 seconds.   After PCR, the reaction was heated to 95oC for 10 seconds, 
cooled to 4oC and stored at 4oC. The PCR reaction protocol to detect retroviral 
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insertions was 95oC for 15 seconds, 35 cycles of 95oC for 2 seconds, 60oC for 2 
seconds, and 72oC for 4 seconds, followed by 72oC for 30 seconds, cooling to 
4oC and storage at 4oC. PCR was conducted with the following reagents: 1X 
ExTAQ PCR buffer, 1X dNTPs (250 µM each), 1X LCGreen Plus, 0.5 µM 
primers, 1 µl of genomic DNA, and 0.25 U ExTAQ in 10 µl reactions. Following 
the PCR, samples were analyzed for melting curves on a Lightscanner (Idaho 
Technology) over a 65-95oC range.  The temperature was set to increase at 
0.1oC/second. 
PCR primers 
 P53 I166T FWD (F3):  GCGCCTGCTGGTCA 
 P53 I166T REV (F4):  CTGATTGCCCTCCACTCTT 
 APC FWD (F29):  CCACTAATAATGTTGCAGCTGA 
 APC REV (F30):  GACTGATGATTGGCTCTCAGA 
 BAP28 FWD (K73): AAAGAGGTCAACAAGAAACTG  
 BAP28 REV (K74):  TGAGGAAGAGAGAAATGCTC  
 WDR43 FWD (K51):  ACAAGATTCTTAAGGGATAAAGT  
 WDR43 REV (K56):  GTAAATCATCATTAACATCTATTACC  
 VIRUS REV (K53):  GAGTGATTGACTACCCGTCAG  
 WDR43 FWD (SG9):  CCATCCTCATCTACAGCACACTGA 
 WDR43 REV (SG112):  GGGTTAATGGGACCAACTGA 
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Figure 3.1:  Point mutation genotyping of p53I166T and APCmcr by HRMA.  (a) The 
DNA sequence surrounding the p53 I166T missense mutation.  Primer 
sequences are underlined, and the SNP is denoted by an asterisk above the 
nucleotide.  The Tm of the wild type product is 79.5oC and the mutant product, 
80.9oC.  (b) Melting curves of the PCR products from 48 embryonic DNA 
samples generated by crossing a p53I166T/+ to a p53I166T/+ fish.  Following 
clustering analysis the blue curves denote wild type samples, the red curves 
denote mutant samples, and the black curves denotes heterozygous samples.  
(c) The DNA sequence surrounding the APCmcr missense mutation.  Primer 
sequences are underlined, and the SNP is denoted by an asterisk above the 
nucleotide.  The Tm of the wild type product is 80.9oC and the mutant product, 
82.0oC.  (d) Melting curves of the PCR products from 48 embryonic DNA 
samples generated by crossing a APCmcr/+ to a APCmcr/+ fish.  Following 
clustering analysis, the red curves denote wild type samples, the blue curves 




















Figure 3.2:  Genotyping a small deletion in the BAP28 mutant by melting curve 
analysis. (a) The DNA sequence surrounding the BAP28 deletion mutation.  
Primer sequences are underlined, and the deletion is denoted by dashed lines 
between the nucleotides. The Tm of the wildtype product is 76.8oC and the 
mutant product is 75.2oC. (b) Melting curves of the PCR products from 48 
embryonic DNA samples generated by crossing a BAP28y75/+ to a BAP28y75/+ 
fish.  Following clustering analysis the red curves denote wildtype samples, the 








Figure 3.3:  Genotyping of the retroviral insertion mutant WDR43 by melting 
curve analysis.  (a) Genomic organization of the WDR43 insertion.  (b) The DNA 
sequence of the wildtype allele and the mutant allele. Primer sequences are 
underlined.  The Tm of the wildtype product is 73.0oC and the mutant product is 
81.1oC.  (c) Melting curve of the PCR products from 48 embryonic DNA samples 
generated by crossing a WDR43hi821/+ to a WDR43hi821/+ fish.  Following 
clustering analysis the blue curves denote wildtype samples, the red curve 









MITOTIC CATASTROPHE AND P53-DEPENDENT APOPTOSIS IN  


















A novel gene wdr43 was identified in a zebrafish screen for mutants that 
have phenotypes indicative of activation of the p53 pathway, and are p53-
dependent. Wdr43 mutants have hyperactivated apoptosis, cell cycle arrest and 
p53 autoregulatory pathways, and a decrease in S-phase cells within the cell 
cycle. Strikingly, a subset of cells in wdr43 mutants undergoes p53-independent 
mitotic catastrophe, suggesting that chromosomal instability is responsible for the 
activation of the p53-dependent apoptotic pathway.   
Introduction 
The power to carry out forward genetics screens in Zebrafish allows rapid 
identification of novel genes that function in extremely important signal 
transduction pathways in vertebrates.  P53 is a transcription factor whose 
function is lost in the majority of human cancers.  P53 functions as a tumor 
suppressor and has been touted the “guardian of the genome” for its role in 
protecting the fidelity of DNA by becoming activated in the presence of DNA 
damage (Lane, 1992, 1993).  Consequently, p53 transcriptionally activates 
cohorts of genes, whose protein products induce apoptosis and cell cycle arrest 
in cells in which the genome has been compromised.  In addition, a feedback 
loop in which p53 is post translationally modified also contributes to the activation 
level of p53, for example phosphorylation by CHK2, or degradation of p53, via 
ubiquitination by mdm2 (Castedo et al., 2004; Perona et al., 2008). 
DNA damage and the activation of the p53 pathway can be caused by 





replication and anomalies in mitosis.  Each of these leads to different cellular 
responses in which the damage signal is propagated through different proteins.  
Maintaining the fidelity of the genome is imperative during each cell cycle of 
genome replication and during the lifespan of an organism.  Failure to do so 
results in varying degrees of consequences, ranging from unnoticeable silent 
mutations to fatal disease processes. 
Studying the pathways involving DNA damage has revealed a number of 
genes important to transducing the DNA damage signal.  CHK2 is one of the 
main transducers of the DNA damage signal to p53.  It has been shown that 
CHK2 is capable of phosphorylating p53 in the presence of DNA damage.  CHK2 
can be activated at multiple points in the cell cycle, G1, S and G2/M, and then is 
involved in phosphorylating multiple proteins, including p53 that lead to either 
repair of the damage or apoptosis (Allen et al., 1994; Clarke et al., 1999; Kastan 
and Bartek, 2004; Weinert et al., 1994).   
The extent of DNA damage ranges from small changes in the DNA 
sequence to large changes to entire chromosomes.  The DNA double helix can 
have one or two strands broken as the result of UV or irradiation.  Errors in 
replication are can be made.  If not repaired appropriately, this usually results in 
changes to the DNA sequence.  Large scale changes to chromosomes can be 
seen when errors in mitosis occur.  If the mitotic spindle is not formed correctly, 
or if checkpoints in mitosis are lost, chromosomal instability can occur.  Specific 
genes in these pathways have been identified and serve as a precedent for 





ATM (Ataxia-Telangiectasia Mutated) and ATR (Ataxia-Telangiectasia and 
Rad3 related) are involved in recognizing breaks in the DNA.  ATM has 
specifically been associated with double strand breaks caused by irradiation, for 
example.  Upon recognition of double strand breaks, several proteins are 
recruited to the foci of damage, including the Mre11/Rad50/Nbs1 complex (Lavin, 
2007).  Activation of ATM results in the activation of several cell cycle 
checkpoints.  The G1-S and G2-M checkpoints are activated in p53-dependent 
manner, and results in a decrease of S-phase cells and decreased number of cell 
entering M-phase, respectively (Kastan and Bartek, 2004; Matsuoka et al., 1998).   
Other mechanisms are important to maintaining the fidelity of DNA that 
are upstream of p53.  BRCA1 and DNA ligase IV are two well-studied mutants 
that are embryonic lethal early, and are rescued, or partially rescued, in a p53 
mutant background.  BRCA1 is thought to interact indirectly with Rad51 in 
repairing double strand breaks in the DNA.  Deficiency in BRCA1 causes 
defective DNA repair and defective G2/M cell cycle checkpoints (Deng and 
Brodie, 2000).  Consequently, loss of BRCA1 has been shown to cause 
increased apoptosis and genomic instability in mice.  The degree of rescue is 
dependent on the mutation in BRCA1 as well as the mutation in p53 (Hakem et 
al., 1997; McAllister and Wiseman, 2002; Xu et al., 2001).  BRCA1 has clearly 
demonstrated its importance in hereditary breast cancer, as well as ovarian 
cancer.  DNA ligase IV is involved in repairing double strand breaks during the 





DNA Ligase IV exhibit neuronal apoptosis and are also rescued with concurrent 
deficiency of p53 (Frank et al., 2000; Gao et al., 2000).   
The importance of maintaining the fidelity of the DNA throughout mitosis is 
imperative to cells.  Errors in mitosis have been documented ranging from mitotic 
failure to mitotic catastrophe.  The absence of specific genes has been shown to 
create a DNA damage signal.  In fact, the inhibition of genes like ATM, ATR, 
CHK1, CHK2, Polo like kinase (PLK) 1, PLK2 and PLK3 can induce mitotic 
catastrophe due to the lack of cell cycle checkpoints (Bunz et al., 1998; Castedo 
et al., 2004; Chan et al., 1999; Chen et al., 2003).  Furthermore, the absence of 
genes implicated as having a role in the mitotic spindle can lead to mitotic 
defects.  The aurora kinases function in the mitotic spindle and are responsible 
for phosphorylating specific proteins to initiate phases of mitosis, and are 
necessary for appropriate spindle formation.  In their absence, microtubules do 
not form appropriately, and chromosomal segregation is impaired.  Interesting, 
overexpression of both aurora kinases and PLK1 also causes similar mitotic 
defects, such as tetraploidization and chromosomal aberration.  Importantly, this 
phenotype activates the p53 pathway (Castedo et al., 2004).  In a p53 mutant 
background, this phenotype can persist, suggesting these cells that can continue 
living with chromosomal instability, and possibly predisposed for tumorigenesis.  
Evidence that chromosomal instability, due to mutations in mitotic machinery, can 
lead to tumorigenesis is provided by studies of heterozygous mice deficient in 
Aurora A, which are predisposed for tumors likely due to high rates of aneuploidy 





Understanding the cell biology of how genome integrity is maintained is 
imperative to understanding of many disease processes.  Because p53 has been 
touted as such an important player in maintaining genome integrity, we have 
used it as a center point to search for new genes that, when mutated, cause 
activation of the p53 pathway and p53-dependent embryonic phenotypes.  In this 
paper, we describe a novel gene which functions in the formation of the mitotic 
spindle and metaphase plate.   
Results 
Wdr43 Mutant Recovered from an Embryonic Zebrafish Screen,              
Rescued by Loss of p53 
We conducted a secondary screen on a collection of mutants to find more 
genes in DNA damage pathways that activate p53.  Earlier work in our lab 
identified p53 dependent phenotypes in zebrafish.  These were discovered by 
inducing DNA damage in fish with gamma-irradiation.  Specifically, we saw brain 
necrosis/apoptosis and a curled tail phenotype.  Both of these were rescued with 
the injection of p53 morpholino (Parant et al., 2009).  The Hopkins lab collected 
approximately 350 embryonic lethal mutant lines (Amsterdam et al., 2004; 
Golling et al., 2002).  Examining the published phenotypes of the mutant 
collection, we injected a selected number of mutant lines that possibly displayed 
p53-dependent phenotypes.  In a selected number of these mutants, we knocked 
down p53 via morpholino injection, and scored for rescue of the phenotype 
(Figure 4.1A).  Eleven mutants were recovered from this screen, some of the 





replication protein A1 genes were rescued by p53 morpholino injection; 
deficiencies in these genes are known to p53 dependent cell cycle arrest in 
mammalian studies. These genes provided a proof of principle we were pulling 
out genes involved in the pathways in which we are interested.  This paper will 
focus on one of the novel genes recovered.   
The mutant, wdr43, has an embryonic lethal phenotype only as a 
homozygous mutant.  Heterozygous fish show no discernable phenotypes 
compared to homozygous wild type neither in the embryonic stages nor 
adulthood.  By gross morphology, mutant wdr43 fish showed brain 
apoptosis/necrosis visible at 22 to 24 hpf.  At 48hpf, mutants were easily 
discernable from wild type siblings (Figure 4.1B).  The head and eyes were 
smaller, and a tail phenotype was visible at the caudal end.  Mutants also have 
varying degrees of heart edema.  To confirm the results of our initial screen, p53 
morpholino was injected into wdr43ins/+ - wdr43ins/+ crosses.  The embryos 
displayed consistent Mendelian genetics, i.e. 1:2:1, homozygous wild type 
wdr43+/+: heterozygous wdr43ins/+: homozygous mutant wdr43ins/ins, respectively.  
P53 morpholino rescued homozygous mutants (N=98/100), with a complete 
rescue at 48 hpf (Figure 4.1C).   
Retroviral insertion could alter not only the function of the gene into which 
it is inserted, but also alter functions of genes distant from the insertion site.  To 
affirm the fact the phenotypes we have described were due specifically and only 
to the loss of wdr43, we conducted two experiments.  First, in order to assess 





whether the mutant phenotype could be rescued by injection of wildtype wdr43 
mRNA.  The mutant phenotypes were rescued with the injection of wdr43 mRNA 
(Figure 4.1D.  Although it was not a complete rescue, the mRNA reduced the 
curled tail phenotype and brain apoptosis normally visible at 48hpf (Figure 4.1D, 
N=18/22).  Second, to test whether knockdown of wdr43 conferred the same 
phenotype as the insertional mutation, we injected morpholino designed to block 
splicing of wdr43 transcript.  This morpholino was designed so intron 2 would be 
included in spliced mRNA, introducing a frameshift and a premature stop codon.  
RT-PCR was conducted on cDNAs from morpholino injected embryos.  The wild 
type product disappeared with increasing amounts of morpholino (Supplemental 
Figure 4.1).  The efficacy of the morpholino was shown by RT-PCR of morphants 
compared to wild type fish showing the progressive loss of the wild type allele 
with increasing doses of wdr43 morpholino (Figure 4.1E).  
Because morpholinos sometimes only partially knockdown gene function, 
we used a genetic approach to confirm whether the wdr43 phenotype is p53-
dependent.  A p53 mutant, p53I166T, recently derived from a forward genetic 
screen in our lab, has a mutation in the DNA binding domain of p53, rendering it 
functionally inactive (Parant et al., 2009).  If we injected wdr43 morpholino into 
p53 homozygous mutants, we again saw a rescue of the phenotype (Figure 4.1F, 
N=96/100).  Lastly, we bred our wd43 mutant into the p53 mutant line, and again, 
we saw rescue of the phenotype at 48hpf (Figure 4.1G).  Although the double 





mutant, the double mutant was not viable; it died at about 5-6 days post 
fertilization.   
Loss of wdr43 Activates p53 Pathway and Apoptosis  
In normal conditions p53 exists at low levels.  Insults to the cell that 
activate the pathway cause p53 transcript levels to increase and a stabilization of 
the p53 protein.  In general, p53 can activate three different pathways: apoptosis, 
cell cycle arrest, and an autoregulatory loop via mdm2 (Figure 4.2A).  As a 
transcription factor, and in order to activate the three pathways, p53 targets 
several downstream genes.  To assess whether p53 target genes were 
aberrantly activated in wdr43 mutants, we conducted real time PCR analysis of 
several downstream genes in the presence and absence of wdr43.  The cDNA 
samples of wild type siblings and mutant were normalized to beta actin.  The 
expression levels in the mutant were divided by those in wild type siblings’ 
samples to give the fold change between the two samples.  The apoptotic p53-
response genes, bax, puma and noxa, had elevated expression levels of 
approximately 3- to 6.5-fold.  The cell cycle arrest genes, p21 and cyclin G, were 
upregulated 3- to 4-fold.  The p53-regulatory gene mdm2 was up approximately 
7.5 fold (Figure 4.2B).  Together, these results indicate that wdr43 homozygous 
mutants have aberrantly activated the expression of cohorts of p53 target genes. 
Since the initiation of apoptosis is one of the main roles of p53, we 
examined apoptosis in developing embryos using a live stain, acridine orange 
(AO), which differentially stains apoptotic cells with a punctate pattern due to the 





is not to be confused with autofluorescence often visible in an embryo.  At 24hpf, 
an increased level of apoptosis was quite evident in mutant embryos (Figure 
4.2C, D, N=100).  Apoptosis appeared to be increased throughout the embryo, 
but is particularly evident throughout the neural tube.  The levels of apoptosis in 
p53;wdr43 double homozygotes were comparable to wildtype levels (Figure 
4.2E), indicating that the increased levels of apoptosis seen in wdr43 mutants 
was p53 dependent. 
Genetic Modulation of the p53 Pathway by bcl2 mRNA and CHK2        
Morpholino Partially Rescued wdr43 Homozygous Mutants 
The results described above provide genetic evidence the wdr43 mutant 
phenotype is p53-dependent and the p53-dependent pathways were activated in 
the wdr43 mutant. However, these results do not reveal where wdr43 intersects 
the p53 pathway.  To test whether the wdr43 mutant activates the p53 pathway 
by activating the arm between p53 and apoptosis, we explored whether the p53 
pathway remained responsive to bcl2 mediated inhibition of apoptosis in wdr43 
mutants. Bcl2 is a known anti-apoptotic gene capable of intervening in the steps 
between p53 activation and apoptosis by inhibiting the p53 downstream apoptotic 
response.  Bcl2 was overexpressed by mRNA injection into clutches of embryos 
from wdr43 heterozygous crosses.  Bcl2 mRNA at least partially rescued the 
mutant phenotype at 48hpf (Figure 4.3 A, B, C, D; N=25/30).  The tail of the 
mutant embryo with bcl2 mRNA did not exhibit the same phenotype as an 
uninjected mutant.  Also, there appeared to be less apoptosis in the head of the 





between p53 activation and apoptosis is intact and responsive to bcl2 regulation. 
This suggests that the wdr43-dependent activation of the p53 pathway occurs 
upstream of the bcl2 modulated step. 
In contrast to bcl2, which functions downstream of p53 to modulate 
apoptosis, CHK2 functions upstream of p53, by phosphorylating p53 in response 
to DNA damage signals, leading to p53 protein stabilization and activation 
(Matsuoka et al., 1998; Perona et al., 2008). To test whether CHK2 functions in 
the same genetic pathway as wdr43, we injected CHK2 morpholino into embryos 
from wdr43 heterozygote crosses, and examined wdr43 mutant embryo 
phenotypes.  Knockdown of CHK2 partially rescued the wdr43 mutant 
phenotypes (Figure 4.3 E, F).  The mutant tail phenotype was less prominent and 
there was less apoptosis visible in the neural tissues.  These results indicate that 
wdr43 mutant phenotype is at least partially dependent on the function of CHK2, 
implicating wdr43 in the transmission of signals for genome instability or DNA 
damage.  
Cell Cycle Analysis Shows Decrease of Cells in S phase in Mutant          
Embryos 
Considering CHK2 can be activated by defects in all parts of the cell cycle, 
we examined the cell cycle in wdr43 mutants versus wild type siblings.  Embryos 
were homogenized into cell suspensions, stained with propidium iodide and 
processed in a FACScan machine. Cell cycle was analyzed at the developmental 
stage at which brain necrosis was grossly visible, at approximately 24hpf, 





difference in the cell cycle was the amount of cells in S-phase, or during the 
process of DNA replication, when the cell has between 2n and 4n DNA content.  
The mutants had a statistically significant lower number of cells in S-phase.  
Interpreting cell cycle analysis in whole zebrafish embryos poses a problem.  
Because whole embryos are homogenized, many cell types are present in the 
suspension.  Therefore, there is a variety of cell sizes present, and perfect peaks 
in cell cycle, particularly at a young age, are difficult to obtain.  Nonetheless, 
even with the variable background of cells derived from whole embryos in which 
cell cycles are not synchronized, these data indicate mutants have fewer cells 
that are resident in S-phase at this stage of development, suggesting the 
possibility that wdr43 mutants have a defect in mitosis.   
wdr43 Mutants Have Mitotic Spindle Defect 
In order to assess whether wdr43 mutants have a cell cycle defect in 
mitosis (M-phase) fixed whole embryos in mutants and wild type siblings were 
stained with an antibody to alpha-tubulin, to reveal microtubules, and with an 
antibody to phosphorylated histone H3 (pH3). Histone H3 is phosphorylated only 
during mitosis, and serves as a useful chromatin stain that is indicative of a cell in 
mitosis.  In wild type sibling embryos, normal mitosis generates a well-organized 
metaphase plate stained with anti-pH3 and a spindle apparatus of microtubules, 
with two poles (Figure 4.5A; 100%, N=100/100). In contrast, wd43 mutants have 
defective mitotic figures in approximately 23% of cells stained with pH3 at 24hpf 
(Figure 4.5B, N= 46/200).  In these defective mitotic cells, microtubules do not 





Similarly, the chromatin in defective cells was not lined up in an orderly 
metaphase plate.  This suggests that wdr43 is involved in ensuring normal 
mitosis and segregation of replicated DNA.  Every mutant embryo examined 
(N=30) displayed metaphase plate defects; however, as noted, not every mitotic 
figure appeared to be abnormal at this level of resolution.   
If the wdr43-dependent metaphase plate defect is an upstream 
component of p53 activation in the wdr43 mutant, then it would be predicted to 
be independent of p53 function. To test this possibility, wdr43; p53 double 
homozygous mutant embryos were examined, and found to have defective 
metaphase plates (Figure 4.5C, N= 18/100) similar to those seen in wdr43 
mutants. 
wdr43 Protein Localizes Around the Mitotic Spindle 
In order to further assess the roles of wdr43 in mitosis, we generated a C 
terminal His-tagged wdr43 protein (His-wdr43).  His-Wdr43 mRNA was injected 
into wild type embryos at the single cell stage.  Embryos were collected at 24 hpf 
and immunohistochemistry was performed to detect microtubule arrays (anti-
alpha-tubulin) and the epitope-tagged wdr43 protein (anti-6X-His).  Although the 
staining patterns were sporadic as expected for an ectopic protein expressed by 
mRNA injection, one reproducible hallmark was the localization of wdr43 near 
microtubule spindle apparati in metaphase stage cells (Figure 4.6 A).  Uninjected 
embryos were used as controls for background levels of anti-6X-His antibody 
immunostaining (Figure 4.6 B).  In interphase cells, His-wdr43 appeared to 





4.6 C, D).  Thus, the wdr43 protein appears to accumulate in cells undergoing 
mitosis, consistent with the mitotic phenotype seen in wdr43 mutants.   
Discussion 
Here we describe a zebrafish secondary mutant screen that has 
uncovered mutants with embryonic lethal phenotypes that are dependent on the 
p53 pathway.  A novel gene, wdr43, is required for normal formation of the 
mitotic spindle and metaphase chromatin plate. In the absence of wdr43, a 
subset of cells undergo mitotic catastrophe, and the p53-dependent pathway is 
activated, resulting in apoptosis and embryonic lethality (Figure 4.7).  Partial 
rescue with the CHK2 morpholino suggests the signal is transduced to p53 via 
CHK2.  Strikingly, mitotic catastrophe in wdr43 mutants is not dependent on the 
p53-dependent pathway, suggesting mitotic catastrophe is upstream of p53-
dependent apoptosis. This explains the reason that p53 morpholino, or a 
functionally deficiently p53 mutant background, rescued the wdr43 mutant 
phenotype.  Also, it explains why wdr43 mutants still die.  Mutant p53 does not 
allow mitotically defective cells to initiate the apoptotic response, explaining why 
double homozygous mutants live longer and early embryos (24hpf-48hpf) look 
phenotypically normal. 
The p53 pathway can be activated as a result of many cellular 
mechanisms.  The study of DNA damage, mitosis, and autoregulation of p53 has 
revealed many genes important to the activation and regulation of the pathway.  
Designing a screen using p53 allows us a unique opportunity to find genes that 





the mitotic spindle in dividing cells.  In the absence of wdr43, mitotic spindle 
aberrations occur, and this signal appears to be transduced to p53.  This 
activation of p53 results in large scale apoptosis in the developing embryo.   
An interesting trait of this wdr43 mutant is the partial penetrance of the 
mitotic spindle defect.  Although mitotic spindle defects appear in 100% of mutant 
embryos, only 23% of mitotic cells at 24hpf had spindle aberrations.  There are at 
least three possible explanations for this incomplete penetrance. First, it is 
striking that wdr43 mutant embryos develop fairly normally during the first days 
postfertilization, implying that most mitoses must have occurred normally, or at 
least sufficiently enough to not induce widespread developmental arrest and/or 
apoptosis.  Mutant embryos are derived from crosses of heterozygotes, so it is 
possible that heterozygous females produce eggs that contain sufficient 
maternally provided wdr43 mRNA and/or protein to carry homozygous mutant 
embryos through early development. Thus, the onset of apoptosis at 22-24hpf, 
particularly in rapidly dividing cells of the developing nervous system, might 
reflect the stage at which maternal stores of wdr43 mRNA and protein are 
depleted. However, without a specific anti-wdr43 antibody it is not possible to 
measure maternal stores of the protein. Second, it is possible that the wdr43 
insertional mutant is a hypomorph, not a complete null. Thus, there might be 
sufficient residual wdr43 protein to provide normal mitosis in most cell cycle.  
However, our morpholino, which appears to knockdown all of the wild type 
transcript by RT-PCR, yields the same result.  Third, it is possible that wdr43 is 





example, cell contacts with neighbors, the duration of cell cycle, or specific 
spindle orientations, might make a dividing cell hypersensitive to deficiencies in 
wdr43.  In light of these considerations, further studies of wdr43 and the potential 
mechanisms by which a mutant generates a small number of metaphase 
catastrophes and chromosomal aberrations will have interesting disease 
implications.  If these mitotic catastrophes do lead to chromosomal instability, 
even a small number over a lifetime would increase the propensity for 
tumorigenesis (Jallepalli and Lengauer, 2001). 
Together, these data point to a cellular mechanism that leads to an 
embryonic lethal phenotype in wdr43 mutant embryos.  Abnormal mitoses are 
present in mutant embryos.  DNA is improperly segregated, leading to a mitotic 
catastrophe.  This DNA damage signals to activate the p53 pathway, which then 
initiates an aberrant apoptotic response leading to embryonic death. 
Wdr43 is upstream of p53 activation. Other genes upstream of p53 have 
significant roles in cancer.  For example, loss of BRCA1 activates p53, and in 
mice, loss of BRCA1 can be rescued in a p53 deficient background.  Without 
BRCA1, cells lose the ability to respond appropriately to DNA damage, 
particularly double strand breaks.  Understanding the role of BRCA1 in hereditary 
breast cancer has led to prophylactic treatments and improved management of 
individuals carrying a mutation in this gene.   
Genes that function in mitotic spindle formation have also been shown to 
be important in the study of cancer.  Aurora A is localized to the centrosome and 





phosphorylating multiple factors necessary for spindle formation and proceeding 
through mitosis.  Strikingly, Aurora A deficient mice have a mitotic catastrophe 
that is similar to the wdr43 mutant phenotype that we have described in zebrafish 
embryos.  Aurora A has already been shown to be overexpressed in many 
cancers.  The importance of this regulation suggests that either an 
overexpression or a deficiency can lead to a tumorigenic state.  Further studies 
are necessary to assess whether the mitotic spindle defect in wdr43 mutants 
contributes to cancer.   
 
Materials and Methods 
 
 
Zebrafish Maintenance  
 
Zebrafish (Danio rerio) were maintained on an Aquatic Habitat system  
 
(Florida, USA). Embryos were collected from natural matings and raised as  
 
described (westerfeld, 1995). The AB wildtype strain was used for morpholino  
 





Morpholino antisense oligonucleotides (Gene Tools, Oregon) and mRNA 
synthesized with a mMessage machine SP6 transcription kit (Ambion) were 
injected into the yolk just under the nuclei of 1- to 2-cell stage embryos in a 
volume of 0.5 nl.  p53 splice-blocking morpholino (p53 MO) overlaps to splice 
donor site of exon 2 and intron 2 effectively preventing splicing out of intron 2, (5′- 
cccttgcgaacttacatcaaattct -3′); Working concentrations of p53 MO was 0.5mM.  





splicing out of intron 2, (5’- gatttctcaccaatgtacaatgcag-3’).  0.5nL was injected of 
2mM stock solution.  Capped RNAs were synthesized from these pCR II 
plasmids using the mMessage machine SP6 transcription kit (Ambion). The 
working mRNA concentration for Bcl2 was 300 ng/µl, and wdr43 was 200 ng/µl. 
Acridine Orange 
Apoptosis was assayed by soaking embryos in 50 µg/ml Acridine Orange 
(Sigma) for 45 min and subsequently destained for 15 minutes. Photographs 
were taken using a FITC filter. 
Light Cycle PCR 
Real time RT-PCR was performed on a light cycler PCR machine 
(Roche).The following primer sets were used: p21 (SG1:tgacatcagcgggtttacag 
and i102:ttctgctgcttttcctgaca) , Cyclin G (C11:ccaccatgattgaccaggtgacc and 
C15:agcagcacagacccacac), mdm2 (SG76:ctcggtgctgttcttggagt and 
SG77:cactgcttctcctcctcctg), Bax (SG66:acagggatgctgaagtgacc and 
SG67:gaaaagcgccacaactcttc), Puma (i97:acgctgtcttccttcagagg and 
i98:cctgcagaaaattcccagag), Noxa (i91:atggcgaagaaagagcaaac and 
i92:cgcttcccctccatttgtat), p53 (SG72:accccggatggagataactt and 
SG73:cccagcaactgaccttcctgag), and β-actin (SG86:ggtatgggacagaaagacag and 
SG87:agagtccatcacgataccag). Experiments were done in triplicate and 







Cell Cycle Analysis 
 24hpf embryos were homogenized in an eppendorf tube.  Cells were 
washed three times in PBST, and pelleted at 1500 x g for 30 seconds at 4oC.  
Cells were fixed in 1% paraformaldehyde, washed three more times in PBST and 
repelleted.  -20oC Ethanol was added dropwise to cells, while vortexing, to 
resuspend, and stored overnight at 4oC.  Cells were pelleted, and resuspended 
in solution of propidium iodide (20µg/ml in PBST). 
Immunohistochemistry and Fluorescence Microscopy 
For zebrafish immunohistochemistry of the mitotic spindle, embryos were 
fixed in microtubule stabilization buffer (1X PBS, 3.7% formaldehyde, .25% 
glutaraldehyde, 1mM MgCl2, 5mM EGTA, 0.2% Triton X-100) for three hours at 
room temperature.  Embryos were washed in PBST, then dechorionated, and 
subsequently blocked for 1 hour in PBS containing 10% sheep serum, 1% 
DMSO. Embryos were incubated in primary antibody including mouse anti- 
alpha- Tubulin (1:200), rabbit anti-phospho Histone H3 (Santa Cruz, 1:200), and 
rabbit polyclonal anti-6 His (Covance, 1:100). After washes block solution, 
embryos were incubated in secondary antibodies, including goat anti-rabbit Alexa 
Fluor 647 and donkey anti-mouse Alexa Fluor 488. Embryos were cleared and 
mounted in Slow Fade Reagent (Molecular Probes). Images were acquired using 
an Olympus Fluoview FV300 laser scanning confocal microscope and assembled 
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Figure 4.4:  Cell cycle analysis showed decrease of S-phase cell in wdr43 
mutant at 24hpf.  Wild type (A) and mutant (B) cells were plotted with number of 
cells on the y-axis and the effective DNA content on the x-axis.  Experiments 
were done in triplicate, each counting > 10,000 events.  In the table (C), numbers 


































































































The wdr43 mutant fish was originally recovered due to its embryonic lethal 
phenotype.  Although we saw rescue of early p53 dependent phenotypes, the 
mutant fish still died.  Furthermore, we noticed developmental abnormalities not 
rescued in the p53 mutant background.  Specifically, the gut and eyes did not 
seem to develop normally.  This observation led to a marker analysis in order to 
better understand the developmental phenotypes due to the loss of wdr43.   
 The expression of wdr43 is ubiquitous in the early zebrafish embryo, until 
12hpf (Figure 5.1 A, B) and then it localizes to specific tissues, visible by 26hpf.  
At 26hpf, expression of wdr43 exists in the neural regions of the embryo, 
including the eye, as well as in the tail, exactly where the phenotypes are visible 
(Figure 5.1 C).  By 48hpf, expression is only visible in a small region of the neural 
tissue (Figure 5.1 D).  Interestingly at 72hpf, we see expression of wdr43 arise in 
specific organs.  Expression exists in the developing gut, as well as the otic 
vesicle (Figure 5.1 E).  By 96hpf, wdr43 expression is visible only in the gut. 
At 96hpf (4dpf), the gut in a wild type embryo is visible extending through 
the yolk.  This structure is not present in either the wdr43 mutant or wdr43; p53 
double mutant (Figure 5.2 A-C).  To examine whether a primitive gut tube forms, 
we used an early gut marker, FKD2 (or FoxA3), a marker of endoderm.  At 48hpf, 
wild type, mutant and double mutant guts were indistinguishable by FKD2 in situ 
hybridization (Figure 5.3 A-C).  The first evidence that the gut in the mutant 
develops abnormally comes from looking at FKD2 expression at 72hpf.  The wild 





appeared that single and double mutant guts are stalled and look similar to 48hpf 
staining patterns (Figure 5.3 D-F). 
To see if the mutant gut was able to differentiate, intestinal fatty acid 
binding protein (iFABP) was used as a marker at 96hpf.  Normally, this marker is 
visible starting at approximately 72hpf in wild type gut and is a marker of 
differentiated enterocytes.  Wild type, single and double mutant embryos were 
collected at 96hpf and underwent in situ hybridization for iFABP.  This marker 
was clearly visible in the wild type gut, but not in either the single or double 
mutant gut (Figure 5.3 G-I).  The combination of FKD2 and iFABP staining 
showed that mutants were able to form a primitive gut but not differentiate, and 
this phenotype was independent of p53.   
This finding was verified in plastic sections of the three different guts at 
96hpf.  The wild type gut exhibited architecture indicative of a gut developing 
normally.  The cells were well organized and the columnar epithelium was visible.  
The beginning of crypt formation was also evident (Figure 5.3 J).  The guts of 
wdr43 mutants and wdr43; p53 double mutants did not have the same 
appearance.  The cells were not well organized, and they did not appear to be 
columnar epithelium.  The cells were more cuboidal in structure with larger 
nuclei.  Crypt formation was not evident in either the single or double mutant 
(Figure 5.3 K, L).  In essence the mutant and double mutant guts looked like 
more primitive guts, approximately that of a 48hpf wild type embryo. 
Eye morphology was also affected in both wdr43 morphants and wdr43 





and the cells did not appear to be as well organized as in wild type embryos.  
Similar to the gut, it appeared the eyes were able to begin development normally.  
We have verified that early development of the eye proceeds appropriately with 
several early eye markers, including bmp4, rx3, and tbx5 (Figure 5.5).  Later eye 
markers are necessary to determine if they do not develop past a certain point. 
Because there appeared to be issues with gut and eye differentiation, we 
looked to see if this issue was global or specific.  In this case we looked at heart 
differentiation.  We sought a marker for a gene that would not arise until after we 
see defects in the other organs, approximately 3dpf.  Tropoelastin is a marker of 
the outflow tract of the heart.  This marker is present at 3-4dpf in wild type 
embryos, and seemed to be the perfect candidate to test against our mutants.  At 
4dpf, tropoelastin was visible in wild type, mutant and double mutant embryos.  
This implied other organs in the embryo were able to differentiate, even at this 
later timepoint, implying the specificity of the gene in organ development 
The gut and eye were not the only visible p53 independent phenotypes in 
the embryos.  The pectoral fin also did not develop appropriately.  The 
combination of these three developmental phenotypes, inability for gut to 
differentiate, inability for eye to develop, and inability for the pectoral fin to 
develop are very reminiscent of phenotypes seen in fish deficient in APC or 
Retinoic Acid pathway components.  In APC morphant embryos, we saw a 
misregulation of wdr43 at 72hpf, although this finding needs to be verified.  In situ 
hybridization showed wdr43 expression in through the head region, yet not in the 





constricted to the developing gut.  Although this piece of data is intriguing, more 
experiments are necessary to link wdr43 to this pathway.   
These data provide evidence that wdr43 functions in development in a p53 
independent manner.  We have shown some data that suggest wdr43 is 
necessary for gut development, specifically the differentiation that occurs around 
72hpf in the zebrafish.  Many similar phenotypes exist between the wdr43 mutant 
embryos and phenotypes indicative of the APC/RA pathway; however, more data 



































































































Zebrafish offer very unique attributes to study the genetics of human 
disease.  Its attributes as a model organism make it well poised to offer insight 
into the genetics pathways involved in disease and the discovery of novel genes 
implicated.  The work presented in this thesis describes the use of zebrafish to 
develop a new model of the genetic syndrome Li-Fraumeni.  We describe a p53 
mutant in zebrafish and its propensity toward tumor development.  Next, a novel 
method of genotyping various zebrafish mutants is described.  High Resolution 
Melting Analysis (HRMA) has the sensitivity to differentiate melting points of DNA 
duplexes representing wild type and mutant alleles.  Finally, the novel gene 
wdr43, is identified in another forward genetics screen.  The p53 dependent 
characterization of this gene reveals a role in the mitotic spindle.  P53 
independent observations indicate wdr43 has a role in specific tissue 
development in zebrafish. 
Li-Fraumeni Model 
A forward genetics screen recovered a zebrafish line with a mutation in 
the DNA binding region of p53.  The I166T amino acid change rendered the gene 
not functional in the sense that although the p53 is stabilized following DNA 
damage, it does not transactivate downsteam target genes.  This model not only 
exhibited p53 pathway phenotypes at the embryonic level, but adult fish 
developed tumors with 100% penetrance.  Furthermore, this was the first 
indication of Loss of Heterozygosity in zebrafish, offering more validation of using 





loss of function allele and can rescue mdm2 lethality.  This p53 mutant provided 
more than a Li-Fraumeni model; it provided a key tool to use in genetics assay to 
find more about cellular and disease mechanisms involving p53. 
This forward genetics screen, based on an apoptosis assay, will continue 
to find additional mutants that show no, or less, apoptosis following irradiation.  
The identification of the p53 mutant provided a proof of principle that screen will 
reveal genes of interest.  Ideally, we will recover novel genes that function in this 
pathway, either upstream or downstream of p53.  Precedents exist for both of 
these possibilities.  An upstream gene would not transduce a DNA damage 
signal to p53.  An example of a known gene would include ATM, a gene that 
recognizes double strand breaks in DNA.  A downstream gene would not be able 
to transduce the p53 initiated apoptotic signal.  The caspases involved in the 
apoptotic pathway are examples of downstream genes.  To date, we are far from 
saturation in this screen, so the possibility of recovering more mutants as a result 
of screening more genomes is likely. 
Also, a modifier screen is currently underway.  This screen was devised 
by ENU mutagenesis of p53 mutants to create G0 fish.  A dominant screen at the 
F1 generation can be carried out to find modifiers of p53 that enable the fish to 
get tumors earlier than a normal p53 mutant cohort.  Activating mutations in 
oncogenes would be examples of genes expected to be recovered.  A recessive 
screen at the F3 generation is also possible.  In this case, tumor suppressors 





pathway are both mutated, the propensity for tumors would be greater than in the 
p53 mutant alone.   
Complementation screens will be conducted to find other alleles of p53.  
This screen is designed such that screened fish are heterozygous for p53 and 
mutagenized fish are heterozygous for another allele of p53.  When crossed, if 
both alleles are inherited, and complementary, mutants will not have a functional 
p53.  This screen will also pick up nonallelic noncomplementation mutants.  This 
would describe two genes, p53 and another gene, that when both are 
heterozygous, cause a phenotype similar to homozygous p53 mutants.   
Zebrafish are ideal model organism for drug screening.  Because they are 
a vertebrate organism capable of producing many offspring, drug screening of 
thousands of small molecules is possible.  A screen currently underway is a 
synthetic lethal drug screen.  The goal of this screen is to find small molecules 
which kill only p53 homozygous mutants and not wild type embryos.  This is 
analogous to the tumor environment in humans.  Because the majority of tumors 
have a mutated p53, while the rest of the affected individual has wild type p53, a 
drug that kills only mutated p53 cells could be a very effective therapeutic.   
High Resolution Melting Analysis to Genotype Animal Models 
The discovery of this mutant, as well as the establishment of many other 
mutant lines, has necessitated the need for efficient and accurate methods of 
genotyping in zebrafish.  High resolution melting analysis (HRMA) describes a 
PCR based technique that is able to genotype based on differences in melting 





small products and the use of a DNA stain, LC Green plus.  This stain emits 
fluorescence when DNA duplexes are bound, but not when the duplex is 
separated after the melting temperature was reached.  Small changes, even from 
a single point mutation, can be detected in PCR products.  We showed the 
efficacy of this technique in multiple types of mutations, including point mutations, 
a small deletion, and a retroviral insertion.  The usefulness of this tool to 
genotype is clear; however, additional uses for HRMA such as mutation scanning 
are a distinct possibility and could dramatically improve on existing tools 
available in zebrafish.  HRMA is already used for mutation scanning for genes in 
humans.  A likely future possibility for using HRMA is for TILLING.  Currently, 
TILLING requires a cumbersome protocol to discover new mutations in genes of 
interest, including a specific, rare enzyme, Cel1, and a Li-Cor machine.  Using 
HRMA to detect mutations in genes of interest may be an efficient way to scan 
genes of interest for new mutations.   
Identification of Novel Gene wdr43 
A different type of forward genetics screen recovered novel gene wdr43.  
This screen highlights the advantage of zebrafish to use morpholino technology, 
targeted knock down of a specific gene, to conduct a screen for other genes with 
genetic linkage to p53.  Data show that loss of wdr43 activates the p53 pathway.  
Immunohistochemistry indicate 23% mitotic figures cannot properly form the 
spindle or metaphase plate.  This disorganized array of microtubules likely leads 
to chromosomal instability, or mitotic catastrophe, activating the p53 pathway.  





DNA, and cell death is inevitable.  This chapter highlights the possibility of 
discovering novel genes that play a role in very important pathways. 
The next step of this project is to determine whether or not this gene has a 
causative role in tumor development.  Currently, we have set up cohorts of wdr43 
heterozygous and wild type fish to see if tumors develop in mutants.  These 
cohorts are set with and without the p53 mutant background.  In normal 
circumstances, zebrafish do not develop tumors.  Comparing fish in a wild type 
p53 background will tell us if heterozygotes have a propensity towards 
tumorigenesis.  In the p53 mutant background, we can see if wdr43 
heterozygosity decreases the time for fist to develop tumors.  Depending on the 
results of these tumor cohorts, wdr43 may establish itself as a gene important to 
tumor formation.  We have some preliminary data that suggest an upregulation of 
wdr43 in human tumors.  These data could imply a fine tuned regulation of wdr43 
is necessary, similar to regulation of Aurora A.  Depending on the results of these 
studies, inhibition or activation of wdr43 may or may not be beneficial to tumor 
therapy.  Preliminary studies of specific inhibitors of Aurora A have entered drug 
trials, yet it is debatable whether or not they will be efficacious, based on the 
evidence that heterozygous mice deficient in Aurora A have a propensity for 
tumors.   
P53 Independent Role of wdr43 in Development 
The p53 independent role of wdr43 in development was also examined.  
The concurrent loss of p53 was not enough to completely rescue the phenotype 





Specifically, the gut, the eye and pectoral fin were developmentally delayed or 
stalled in the wdr43; p53 double homozygous mutant.  Marker and histological 
analysis of the gut show a primitive gut tube is formed, but it does not have the 
ability to differentiate.  The eye has a similar phenotype- it begins development 
normally, but stalls at some timepoint.  This phenotype appears to be specific to 
these organs, because other organs, like the heart, do have the ability to 
differentiate at a similar timepoint.  It is possible that wdr43 is regulated by the 
APC/RA pathway, although further experiments are necessary to make this 
conclusion. 
Further experiments are necessary to definitively place wdr43 in or out of 
the APC/RA pathway.  Misregulation of wdr43 in mutant/morphants in 
downstream components of the APC/RA pathway could help to pinpoint the 
regulation of wdr43.  Epigenetics experiments with these genes could help to 
understand the function of wdr43.   
